WO2005113508A1 - Stable crystal of 4-oxoquinoline compound - Google Patents

Stable crystal of 4-oxoquinoline compound Download PDF

Info

Publication number
WO2005113508A1
WO2005113508A1 PCT/JP2005/009604 JP2005009604W WO2005113508A1 WO 2005113508 A1 WO2005113508 A1 WO 2005113508A1 JP 2005009604 W JP2005009604 W JP 2005009604W WO 2005113508 A1 WO2005113508 A1 WO 2005113508A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
compound
mixture
crystal form
stirred
Prior art date
Application number
PCT/JP2005/009604
Other languages
French (fr)
Inventor
Motohide Satoh
Takahisa Motomura
Takashi Matsuda
Kentaro Kondo
Koji Ando
Koji Matsuda
Shuji Miyake
Hideto Uehara
Original Assignee
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005113508(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2566922A priority Critical patent/CA2566922C/en
Priority to EP17186674.2A priority patent/EP3281939B1/en
Priority to SI200531572T priority patent/SI1636190T1/en
Priority to RS20120306A priority patent/RS52375B/en
Priority to ES05726243T priority patent/ES2388441T3/en
Priority to DK05726243.8T priority patent/DK1636190T3/en
Priority to EP23203885.1A priority patent/EP4299563A3/en
Priority to PL05726243T priority patent/PL1636190T3/en
Priority to CN2005800161426A priority patent/CN1956961B/en
Priority to BRPI0510114A priority patent/BRPI0510114B8/en
Priority to AU2005245296A priority patent/AU2005245296B2/en
Application filed by Japan Tobacco Inc. filed Critical Japan Tobacco Inc.
Priority to MXPA06013405A priority patent/MXPA06013405A/en
Priority to EP05726243A priority patent/EP1636190B1/en
Priority to NZ551839A priority patent/NZ551839A/en
Publication of WO2005113508A1 publication Critical patent/WO2005113508A1/en
Priority to HK06105469.5A priority patent/HK1083341A1/en
Priority to IL179250A priority patent/IL179250A0/en
Priority to NO20065790A priority patent/NO339223B1/en
Priority to HRP20120681TT priority patent/HRP20120681T1/en
Priority to NO20161297A priority patent/NO20161297A1/en
Priority to NO20190051A priority patent/NO20190051A1/en
Priority to NO20200873A priority patent/NO20200873A1/en
Priority to NO20220690A priority patent/NO20220690A1/en
Priority to NO20230913A priority patent/NO347902B1/en
Priority to FR23C1040C priority patent/FR23C1040I1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • the present invention relates to a stable crystal of 6- (3- chloro-2-fluorobenzyl) -1- [ (S) -l-hydroxymethyl-2-methylpropyl] -7- methoxy-4-oxo-l , 4-dihydroquinoline-3-carboxylic acid
  • the present invention also relates to a pharmaceutical composition comprising the crystal or the mixed crystal.
  • such compound is preferably a crystal, particularly preferably a stable crystal.
  • the most stable crystal is generally selected. While the above-mentioned application describes compound A, no concrete description relating to the crystal form of compound A is found.
  • the present inventors have studied various crystal forms of compound A in an attempt to find a stable crystal of compound A. As a result, they have found that compound A has crystal polymorphism, and a crystal of compound A having a particular crystal form is useful as a stable crystal, and based on which findings, they have completed the present invention.
  • an integrase inhibitor comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above- mentioned [5] or [6] as an active ingredient
  • an antivirus agent comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above- mentioned [5] or [6] as an active ingredient
  • an anti-HIV agent comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above- mentioned [5] or [6] as an active ingredient
  • an anti-HIV composition comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above-mentioned [5] or [6] and, one or more kinds of other anti- HIV active substances as active ingredients
  • an anti-HIV agent for a multiple drug therapy with other anti-HIV agent which comprises the crystal of any of the above- mentioned [1]
  • Fig. 1 shows multiple records of X-ray powder diffraction patterns, wherein the upper line shows the diffraction pattern of crystal form III, the middle line shows the diffraction pattern of crystal form I, the lower line shows the diffraction pattern of crystal form II, the vertical axis shows diffraction intensity (cps: counts per second: intervals of scale is 2500 cps) and the transverse axis shows diffraction angle 2 ⁇ (°).
  • Fig. 2 shows multiple records of X-ray powder diffraction pattern obtained from the sample after 3-day preservation of the stability test of crystal form I.
  • the uppermost line shows the diffraction pattern (initial conditions) of crystal form II
  • the lowermost line shows the diffraction pattern (initial conditions) of crystal form I.
  • Shown from the second line are diffraction patterns under preservation condition #6 (60°C/75% R.H.
  • the vertical axis shows diffraction intensity (cps: counts per second: intervals of scale is 2500 cps) and the transverse axis shows diffraction angle 2 ⁇ (°) •
  • the crystal or mixed crystal of compound A of the present invention has the above-mentioned particular crystal form and is superior in physical and chemical stability, which in turn has advantage that maintenance of the quality of compound A for a long-term becomes possible, which facilitates preservation. In addition, they have advantage that handling during production of various pharmaceutical compositions and bulk is easy, which reduces the production cost.
  • the "crystal form II" of compound A means a crystal of compound A, which has an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2 ⁇ (°) of 6.56, 13.20, 19.86, 20.84, 21.22, 25.22° as measured by X-ray powder diffractometer.
  • the "crystal form III" of compound A means a crystal of compound A, which has an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2 ⁇ (°) of 8.54, 14.02, 15.68, 17.06, 17.24, 24.16, 25.74° as measured by X-ray powder diffractometer.
  • the diffraction peak value at the above-mentioned diffraction angle 20 (°) may show slight measurement error due to the measurement instruments or measurement conditions and the like.
  • the measurement error may be within the range of ⁇ 0.2, preferably +0.1, more preferably ⁇ 0.06.
  • the crystal of compound A of the present invention is also characterized by thermal analysis.
  • the enthalpy of endothermic peak is about 81 J/g
  • extrapolated onset temperature is 162.1 ⁇ 5.0°C, preferably 162.1 ⁇ 3.0°C, more preferably 162.1 ⁇ 1.0°C
  • the "extrapolated onset temperature” means, as defined by JIS K 7121 (measurement method of transfer temperature of plastic) , the temperature at an intersection of the extrapolated baseline of the lower temperature side toward the higher temperature side with the tangent line drawn at the point showing the greatest slope on the leading edge of the melting peak on a lower temperature side in a DSC curve.
  • the crystal of compound A is stable.
  • the crystal of compound A of the present invention may be either a crystal form II or a crystal form III, or a mixed crystal of a crystal form II and a crystal form III.
  • the crystal form II or crystal form III is preferable because they are stable crystals, and a crystal form III is more preferable because it is the most stable crystal.
  • a crystal form II is preferable in view of the absorbability by living organisms upon administration as a pharmaceutical composition.
  • the "purity of crystal” means the purity of the crystal form II or crystal form III of compound A.
  • a mixed crystal of a crystal form II and a crystal form III it means the ratio of crystal relative to the total amount of substance of a crystal form II and a crystal form III.
  • the purity of the crystal of the present invention can be determined by, for example, known methods such as X-ray powder diffractometry, thermal analysis and the like.
  • the purity of the crystal or mixed crystal of the present invention does not need to be 100%, and may be not less than 70%, preferably not less than 80%, more preferably not less than 90%, more preferably not less than 95%, and most preferably not less than 98%. Purity within this range is preferable for guaranteeing the quality.
  • the crystal or mixed crystal of compound A of the present invention can be administered to a mammal (human, mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey etc.) and the like as various pharmaceutical compositions such as anti-HIV agents , HIV integrase inhibitors , antivirus agents and the like used for, for example, the prophylaxis and/or treatment of AIDS.
  • a mammal human, mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey etc.
  • various pharmaceutical compositions such as anti-HIV agents , HIV integrase inhibitors , antivirus agents and the like used for, for example, the prophylaxis and/or treatment of AIDS.
  • the crystal or mixed crystal of compound A of the present invention is used as a pharmaceutical composition, it is admixed with pharmaceutically acceptable carriers, excipients, diluents , extending agents , disintegrants , stabilizers , preservatives, buffers, emulsifiers, flavoring agents, coloring agents, sweetening agents, thickeners, correctives, dissolution aids , and other additives , that are generally known per se , such as water, vegetable oil, alcohol (e.g., ethanol or benzyl alcohol etc.), polyethylene glycol, glycerol triacetate, gelatin, carbohydrate (e.g., lactose, starch etc.), magnesium stearate, talc, lanolin, petrolatum and the like, formed into tablet, pill, powder, granule, suppository, injection, eye drop, liquid, capsule, troche, aerosol, elixir, suspension, emulsion, syrup and the like by a conventional method, and
  • While the. dose varies depending on age, body weight, symptom, treatment effect, administration method and the like, it is generally 0.01 mg to 1 g per administration for an adult, which is- given once to several times a day orally or in a dosage form of an inj ction such as intravenous injection and the like.
  • An anti-HIV agent is generally required to sustain its effect for a long time, so that it can be effective not only for temporal suppression of viral growth but also for the prohibition of viral re-growth. This means that a prolonged administration is necessary and that a high single dose may be frequently inevitable to sustain the effect for a longer period during night and the like. Such prolonged and high dose administration increases the risk of side effects.
  • one of the preferable modes of the present invention is such compound permitting high absorption by oral administration, and such compound capable of maintaining blood concentration of the administered compound for an extended period of time.
  • prophylaxis of AIDS is meant, for example, administration of a pharmaceutical agent to an individual who tested HIV positive but has not yet developed the disease state of AIDS, administration of a pharmaceutical agent to an individual who shows an improved disease state of AIDS after treatment but who carries HIV still to be eradicated and whose relapse of AIDS is concerned, and administration of a pharmaceutical agent out of a fear of possible infection.
  • the anti-HIV composition of the present invention is used for, for example, a multiple drug combination therapy of AIDS.
  • the "other anti-HIV active substance" to be used for the anti-HIV composition include an anti-HIV antibody, an HIV vaccine, immunostimulants such as interferon and the like, an HIV ribozyme, an HIV antisense drug, an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, an inhibitor of bond between a bond receptor (CD4, CXCR4, CCR5 and the like) of a host cell recognized by virus and the virus, and the like.
  • HIV reverse transcriptase inhibitor examples include Retrovir(R) (zidovudine) , Epivir(R) (lamivudine) , Zerit(R) (sanilvudine) , Videx(R) (didanosine) , Hivid(R) (zalcitabine) , Ziagen(R) (abacavir sulfate) , Viramune (R) (nevirapine) , Stocrin(R) (efavirenz) , Rescriptor (R) (delavirdine mesylate) , Combivir (R) (zidovudine+lamivudine) , Trizivir (R) (abacavir sulfate+lamivudine+zidovudine) , Coactinon(R) (emivirine) , Phosphonovir (R) , Coviracil (R) , alovudine (3 '-fluoro-3 '-
  • HIV protease inhibitor examples include Crixivan(R) (indinavir sulfate ethanolate) , saquinavir, Invirase (R) (saquinavir mesylate), Norvir(R) (ritonavir) , Viracept(R) (nelfinavir mesylate), lopinavir, Prozei (R) (amprenavir) , Kaletra(R) (ritonavir+lopinavir) , mozenavir dimesylate ( [4R- (4 ⁇ ,5 ⁇ ,6 ⁇ ) ]-l,3-bis[ (3-aminophenyl)methyl]- hexahydro-5 , 6-dihydroxy-4 , 7-bis (phenylmethyl) -2H-1 , 3-diazepin-2- one dimethanesulfonate) , tipranavir (3 '-[ (1R) -l-[ (6R) -5,6- dihydro
  • the HIV integrase inhibitor is exemplified by S-1360, L- 870810 and the like
  • the DNA polymerase inhibitor or DNA synthesis inhibitor is exemplified by Foscavir(R), ACH-126443 (L-2' ,3 '-didehydro-dideoxy-5-fluorocytidine)
  • entecavir (IS ,3S , 4S) -9- [4-hydroxy-3- (hydroxymethyl) -2- methylenecyclopentyl]guanine)
  • calanolide A [10R- (10 ⁇ , H ⁇ , 12 ⁇ ) ] -11 , 12-dihydro-12-hydroxy-6 ,6,10, ll-tetramethyl-4- propyl-2H, 6H, lOH-benzo [1 ,2-b: 3 , 4-b ' : 5 , 6-b"] tripyran-2-one)
  • calanolide B NSC-674447 (1,1 '-azobisformamide)
  • Neurotropin (R) Lidakol (R) , Ancer 20 (R) , Ampligen(R) , Anticort(R), Inactivin(R) and the like, PRO-2000, Rev M10 gene, HIV specific cytotoxic T cell (CTL immunotherapy, ACTG protocol 080 therapy, CD4- ⁇ gene therapy) , SCA binding protein, RBC-CD4 complex, Motexafin gadolinium, GEM-92, CNI- 1493, ( ⁇ )-FTC, Ushercell, D2S, BufferGel (R) , VivaGel (R) , Glyminox vaginal gel, sodium lauryl sulfate, 2F5, 2F5/2G12, VRX- 496, Ad5gag2, BG-777, IGIV-C, BILR-255 and the like are exemplified.
  • the anti-HIV activity substance to be used for the anti-HIV composition of the present invention in the multiple drug combination therapy, preferred are an HIV reverse transcriptase inhibitor and an HIV protease inhibitor.
  • Two or three, or even a greater number of pharmaceutical agents can be used in combination, wherein a combination of pharmaceutical agents having different action mechanisms is one of the preferable embodiments.
  • selection of pharmaceutical agents free of side effect duplication is preferable.
  • the combination of pharmaceutical agents include a combination of a group consisting of efavirenz , tenofovir, emtricitabine , indinavir, nelfinavir, atazanavir, ritonavir + indinavir, ritonavir + lopinavir and ritonavir + saquinavir, didanosine + lamivudine, zidovudine + didanosine, stavudine + didanosine, zidovudine + lamivudine, stavudine + lamivudine and emtriva, and the crystal or mixed crystal of the present invention (Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents.
  • Particularly preferred is a combined use of two agents of the crystal or mixed crystal of the present invention with efavirenz , indinavir, nelfinavir, tenofovir, emtricitabine, zidovudine or lamivudine, and a combined use of three agents of the crystal or mixed crystal of the present invention with zidovudine + lamivudine, tenofovir + lamivudine, tenofovir + zidovudine, tenofovir + efavirenz , tenofovir + nelfinavir, tenofovir + indinavir, tenofovir + emtricitabine, emtricitabine + lamivudine, emtricitabine + zidovudine, emtricitabine + efavirenz, emtricitabine + nelfinavir, emtricitabine + indinavir, em
  • the production method of the crystal or mixed crystal of compound A of the present invention is not particularly limited, and the crystal can be produced by a method known per se or methods shown in the following Examples and the like. Examples While the production method of the crystal of compound A of the present invention is explained in the following by referring to Examples , which are mere examples and do not limit the present invention in any way.
  • Reference Example 1 Production of crystal form I of the compound A
  • Step 1 The compound (148 g, 521 mmol) obtained in Step 1 was dissolved in toluene (750 ml) , thionyl chloride (76 ml, 1.04 mol) and dimethylformamide (catalytic amount) were added, and the mixture was heated under reflux for 2 hr. The insoluble material was filtered off at 60°C, and the filtrate was concentrated under reduced pressure and azeotroped with toluene (330 ml) .
  • the precipitated solid was collected by filtration and the obtained solid was washed successively with 30% aqueous ethanol (500 ml) and a mixed solvent of diethyl ether (150 ml) and hexane (150 ml) and vacuum dried to give 7- fluoro-1- ( (S) -l-hydroxymethyl-2-methylpropyl) -6-iodo-4-oxo-l , 4- dihydroquinoline-3-carboxylic acid ethyl ester (178 g, yield 76%) as a beige solid.
  • TBDMS means a tert-butyldimethylsilyl group.
  • the compound (80 g, 179 mmol) obtained in Step 3 was dissolved in dimethylformamide (320 ml) , imidazole (16 g, 233 mmol) and tert-butyldimethylsilyl chloride (30 g, 197 mmol) were added, and the mixture was stirred at room temperature for 1.5 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous ammonium chloride solution and saturated brine, and dried over sodium sulfate. The organic layer was filtered and the filtrate was concentrated under reduced pressure.
  • the compound (76 g, 136 mmol) obtained in Step 4 was dissolved in tetrahydrofuran (600 ml) and, under an argon stream, dibenzylidenacetonepalladium(II) (3.2 g, 5.5 mmol) and trifurylphosphine (2.6 g, 11.0 mmol) were added, and a solution of the aforementioned IM 3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran (178 ml, 178 mmol) was added dropwise at 60°C. After the completion of the dropwise addition, the mixture was stirred with heating at the same temperature for 2 hr.
  • reaction mixture was allowed to cool to room temperature, saturated aqueous ammonium chloride solution was added, and the mixture was filtered through celite. The filtrate was extracted twice with ethyl acetate. The organic layer was washed successively with water (twice) and saturated brine, and dried over magnesium sulfate.
  • the compound (48 g, 86 mmol) obtained in Step 5 was dissolved in methanol (300 ml) , water (5 ml) and 28% sodium methoxide methanol solution (176 ml, 862 mmol) were added, and the mixture was heated under reflux for 24 hr.
  • the reaction mixture was allowed to cool to room temperature and the mixture was neutralized by adding 6N hydrochloric acid. Methanol was evaporated under reduced pressure. Water was added to the obtained solution and the mixture was stirred. The precipitated solid was collected by filtration and the obtained solid was dissolved in ethyl acetate.
  • the mixture was washed with water and dried over sodium sulfate. The solution was filtered and the filtrate was concentrated under reduced pressure.
  • the obtained residue was recrystallized from ethyl acetate-hexane to give a compound (32 g, yield 86%) as a white solid.
  • the obtained compound (32 g) was dissolved in butyl acetate (160 ml) by heating under reflux, and crystal form II was seeded at 75°C. The mixture was stirred for 3.5 hr while allowing to cool as it was. The precipitated solid was collected by filtration, washed with butyl acetate (25 ml) and vacuum dried to give a compound (25 g, yield 77%) as a white solid.
  • Step 1 The compound (148 g, 521 mmol) obtained in Step 1 was dissolved in toluene (750 ml), thionyl chloride (76 ml, 1.04 mol) and dimethylformamide (catalytic amount) were added, and the mixture was heated under reflux for 2 hr. The insoluble material was filtered off at 60°C, and the filtrate was concentrated under reduced pressure and azeoptoped with toluene (330 ml) .
  • the compound (150 g, 335 mmol) obtained in Step 3 was dissolved in dimethylformamide (500 ml), imidazole (30 g, 0.436 mmol) and tert-butyldimethylsilyl chloride (56 g, 369 mmol) were added, and the mixture was stirred at room temperature for 1.5 hr. Water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was washed successively with water, saturated aqueous ammonium chloride solution and saturated brine, and dried over sodium sulfate.
  • the compound (43 g, 74 mmol) obtained in Step 5 was dissolved in methanol (280 ml) , 28% sodium methoxide methanol solution (151 ml, 742 mmol) and water (4.3 ml) were added, and the mixture was heated under reflux for 20 hr.
  • the reaction mixture was filtered through celite. The filtrate was concentrated under reduced pressure.
  • Water (400 ml) was added to the residue, and the mixture was washed with hexane (100 ml) .
  • the aqueous layer was acidified by adding concentrated hydrochloric acid (65 ml) , and the mixture was extracted with ethyl acetate.
  • Example 2 Production of crystal form II of the compound A
  • Example 2-1 Production of crystal form II of the compound A Step 1
  • the compound (200 g, 704 mmol) obtained in Step 1 was dissolved in toluene (1000 ml) , thionyl chloride (103 ml, 408 mmol) and dimethylformamide (catalytic amount) were added, and the mixture was heated under reflux for 2 hr. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure and azeotroped with toluene.
  • the obtained solid was subject to slurry washing successively with water and 30% aqueous ethanol (650 ml) and vacuum dried to give a crude product (217 g) .
  • the obtained crude product (217 g) was subject to slurry washing with a mixed solvent of ethyl acetate (650 ml) and hexane (440 ml) with heating under reflux.
  • the compound (150 g, 335 mmol) obtained in Step 3 was dissolved in dimethylformamide (450 ml) , imidazole (27 g, 397 mmol) and tert-butyldimethylsilyl chloride (58 g, 385 mmol) were added, and the mixture was stirred overnight at room ' temperature.
  • Water (900 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (680 ml) .
  • the organic layer was washed successively with water (450 ml, 3 times) and saturated brine (200 ml) , and dried over sodium sulfate.
  • the reaction mixture was allowed to cool to room temperature, ethyl acetate (640 ml) and 10% aqueous citric acid solution (400 ml) were added, and the mixture was filtered through Celite, and the filtrate was partitioned. The organic layer was washed successively with water (200 ml) , saturated aqueous sodium hydrogen carbonate (400 ml) and saturated brine (200 ml) , and dried over sodium sulfate.
  • the crude product (193 g) obtained in Step 5 was dissolved in isopropanol (650 ml) , IN aqueous sodium hydroxide solution (1290 ml, 1.29 mol) was added, and the mixture was heated under reflux for 2 hr.
  • the reaction mixture was allowed to cool to room temperature, and filtered through Celite.
  • the filtrate was acidified by adding concentrated hydrochloric acid and the mixture was stirred.
  • the precipitated solid was collected by filtration, and vacuum dried to give a crude product (132 g) as a pale-yellow solid.
  • the crude products obtained in the same manner were combined (total amount 143 g) , suspended in butyl acetate (430 ml) and subject to slurry stirring with heating under reflux for 1 hr.
  • the compound (99 g, 227 mmmol) obtained in Step 6 was dissolved in methanol (530 ml) , 28% sodium methoxide methanol solution (465 ml, 2.28 mol) was added, and the mixture was heated under reflux for 20 hr. The reaction mixture was allowed to cool to room temperature and filtered through Celite. The filtrate- was concentrated under reduced pressure. The residue was acidified by adding water (200 ml) and concentrated hydrochloric acid (190 ml) , and extracted with ethyl acetate (500 ml) . The organic layer was washed twice with water (200 ml) , and dried over sodium sulfate.
  • the crude product (80 L) obtained in Step 4 was dissolved in isopropanol (180 L) , IN aqueous sodium hydroxide solution (180 L, 180 mol) was added, and the mixture was stirred with heating at 50°C for 9 hr.
  • Activated carbon (4.5 kg) was added to the reaction mixture.
  • the mixture was stirred at room temperature for 30 min, filtered through cellulose powder and thoroughly washed with an isopropanol (45 L) - water (45 L) mixture.
  • Water (180 L) and n-heptane (230 L) were added to the filtrate and, after stirring, the mixture was partitioned. The aqueous layer was washed again with n-heptane (230 L) .
  • Example 2-3 Production of crystal form II of the compound A
  • the crystal form II can be also produced by crystallization according to the methods described in Examples 2-3-1 to 2-3-26.
  • Example 2-3-1
  • Example 2-3-2 The compound A (200 mg) obtained in Example 1 was dissolved in 1-butanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (125 mg, yield 63%) of compound A as a white solid.
  • Example 2-3-2 The compound A (200 mg) obtained in Example 1 was dissolved in 1-butanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (125 mg, yield 63%) of compound A as a white solid.
  • Example 2-3-2 The compound A (200 mg) obtained in Example 1 was dissolved in 1-butanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (125 mg, yield 63%) of compound A as a white solid.
  • Example 2-3-3 The compound A (200 mg) obtained in Example 1 was dissolved in butyl acetate (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (102 mg, yield 51%) of compound A as a white solid.
  • Example 2-3-3 The compound A (200 mg) obtained in Example 1 was dissolved in butyl acetate (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (102 mg, yield 51%) of compound A as a white solid.
  • Example 2-3-3 The compound A (200 mg) obtained in Example 1 was dissolved in butyl acetate (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (102 mg, yield 51%) of compound A as a white solid.
  • Example 2-3-4 The compound A (200 mg) obtained in Example 1 was dissolved in methyl isobutyl ketone (2 ml) with heating under reflux. Heptane (2 ml) was added dropwise and the mixture was stirred for 6 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (168 mg, yield 84%) of compound A as a white solid.
  • Example 2-3-4 The compound A (200 mg) obtained in Example 1 was dissolved in methyl isobutyl ketone (2 ml) with heating under reflux. Heptane (2 ml) was added dropwise and the mixture was stirred for 6 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (168 mg, yield 84%) of compound A as a white solid.
  • Example 2-3-4 The compound A (200 mg) obtained in Example 1 was dissolved in methyl isobutyl ketone (2 ml) with heating under reflux. Heptane (2 ml
  • Example 2-3-5 The compound A (200 mg) obtained in Example 1 was dissolved in ethanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (56 mg, yield 28%) of compound A as a white solid.
  • Example 2-3-5 The compound A (200 mg) obtained in Example 1 was dissolved in ethanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (56 mg, yield 28%) of compound A as a white solid.
  • Example 2-3-5 The compound A (200 mg) obtained in Example 1 was dissolved in ethanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (56 mg, yield 28%) of compound A as a white solid.
  • Example 2-3-5 The compound A (200 mg) obtained
  • Example 2-3-6 The compound A (200 mg) obtained in Example 1 was dissolved in methyl ethyl ketone (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 6 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (166 mg, yield 83%) of compound A as a white solid.
  • Example 2-3-6 The compound A (200 mg) obtained in Example 1 was dissolved in methyl ethyl ketone (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 6 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (123 mg, yield 62%) of compound A as a white solid.
  • Example 2-3-7 The compound A (200 mg) obtained in Example 1 was dissolved in methyl ethyl ketone (2 ml) with heating under reflux. Heptane (4 ml
  • Example 2-3-8 The compound A (200 mg) obtained in Example 1 was dissolved in isopropanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (88 mg, yield 44%) of compound A as a white solid.
  • Example 2-3-9 The compound A (200 mg) obtained in Example 1 was dissolved in isopropanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (88 mg, yield 44%) of compound A as a white solid.
  • Example 2-3-9 The compound A (200 mg) obtained in Example 1 was dissolved in isopropanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (88 mg, yield 44%) of compound A as a white solid.
  • Example 2-3-10 The compound A (200 mg) obtained in Example 1 was dissolved in cumene (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (188 mg, yield 94%) of compound A as a white solid.
  • Example 2-3-10 The compound A (200 mg) obtained in Example 1 was dissolved in cumene (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (188 mg, yield 94%) of compound A as a white solid.
  • Example 2-3-10 The compound A (200 mg) obtained in Example 1 was dissolved in cumene (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (188 mg, yield 94%) of compound A as a white solid.
  • Example 2-3-10
  • Example 2-3-11 The compound A (200 mg) obtained in Example 1 was dissolved in anisole (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (107 mg, yield 54%) of compound A as a white solid.
  • Example 2-3-11 The compound A (200 mg) obtained in Example 1 was dissolved in anisole (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (107 mg, yield 54%) of compound A as a white solid.
  • Example 2-3-11 The compound A (200 mg) obtained in Example 1 was dissolved in anisole (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (107 mg, yield 54%) of compound A as a white solid.
  • Example 2-3-11 The compound A (200 mg) obtained
  • Example 2-3-12 The compound A (200 mg) obtained in Example 1 was dissolved in acetone (2 ml) with heating under reflux. Heptane (2 ml) was added dropwise and the mixture was stirred for 16.5 hr while allowing to cool. Heptane (4 ml) was further added, and the mixture was further stirred for 24 hr. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (134 mg, yield 67%) of compound A as a white solid.
  • Example 2-3-12 The compound A (200 mg) obtained in Example 1 was dissolved in acetone (2 ml) with heating under reflux. Heptane (2 ml) was added dropwise and the mixture was stirred for 16.5 hr while allowing to cool. Heptane (4 ml) was further added, and the mixture was further stirred for 24 hr. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (134 mg, yield 67%) of compound A as a white solid.
  • Example 2-3-12
  • Example 2-3-13 The compound A (200 mg) obtained in Example 1 was dissolved in ethanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (129 mg, yield 65%) of compound A as a white solid.
  • Example 2-3-13 The compound A (200 mg) obtained in Example 1 was dissolved in ethanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (129 mg, yield 65%) of compound A as a white solid.
  • Example 2-3-13 The compound A (200 mg) obtained in Example 1 was dissolved in ethanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 hr while allowing to cool. The precipit
  • Example 2-3-14 The compound A (200 mg) obtained in Example 1 was dissolved in 1-propanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (166 mg, yield 83%) of compound A as a white solid.
  • Example 2-3-14 The compound A (200 mg) obtained in Example 1 was dissolved in 1-propanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (158 mg, yield 79%) of compound A as a white solid.
  • Example 2-3-15 The compound A (200 mg) obtained in Example 1 was dissolved in 1-propanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 h
  • Example 2-3-16 The compound A (200 mg) obtained in Example 1 was dissolved in toluene (2 ml) with heating at 100°C. The mixture was stirred for 37 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (190 mg, yield 95%) of compound A as a white solid.
  • Example 2-3-18 The compound A (200 mg) obtained in Example 1 was dissolved in methyl butyl ketone (2 ml) with heating at 60°C. Heptane (1.8 ml) was added dropwise and the mixture was stirred for 37 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (191 mg, yield 96%) of compound A as a white solid.
  • Example 2-3-18 The compound A (200 mg) obtained in Example 1 was dissolved in methyl butyl ketone (2 ml) with heating at 60°C. Heptane (1.8 ml) was added dropwise and the mixture was stirred for 37 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (191 mg, yield 96%) of compound A as a white solid.
  • Example 2-3-18 The compound A (200 mg) obtained in Example 1 was dissolved in methyl butyl ketone (2 ml) with heating at 60°C. Heptane (1.8
  • Example 2-3-19 The compound A (200 mg) obtained in Example 1 was dissolved in chloroform (1 ml) with heating at 60°C. Isopropyl ether (1.8 ml) was added dropwise and the mixture was stirred for 37 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (184 mg, yield 92%) of compound A as a white solid.
  • Example 2-3-19 The compound A (200 mg) obtained in Example 1 was dissolved in chloroform (1 ml) with heating at 60°C. Isopropyl ether (1.8 ml) was added dropwise and the mixture was stirred for 37 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (184 mg, yield 92%) of compound A as a white solid.
  • Example 2-3-19 The compound A (200 mg) obtained in Example 1 was dissolved in chloroform (1 ml) with heating at 60°C. Isopropyl ether (1.8 ml
  • Example 2 The compound A (200 mg) obtained in Example 1 was dissolved in tetrahydrofuran (1 ml) by heating at 60°C. Isopropyl ether (2 ml) was added dropwise and the mixture was stirred for 41 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (144 mg, yield 72%) of compound A as a white solid.
  • Example 2-3-20 The compound A (200 mg) obtained in Example 1 was dissolved in tetrahydrofuran (1 ml) by heating at 60°C. Isopropyl ether (2 ml) was added dropwise and the mixture was stirred for 41 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (144 mg, yield 72%) of compound A as a white solid.
  • Example 2-3-20
  • Example 2 The compound A (200 mg) obtained in Example 1 was dissolved in isobutanol (2 ml) with heating under reflux.
  • Example 2 The compound A (200 mg) obtained in Example 1 was dissolved in butanol (2 ml) with heating under reflux. Heptane (2 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (152 mg, yield 76%) of compound A as a white solid.
  • Example 2 The compound A (200 mg) obtained in Example 1 was dissolved in isobutyl acetate (2 ml) with heating under reflux.
  • Example 2 The compound A (200 mg) obtained in Example 1 was dissolved in isobutyl acetate (2 ml) with heating under reflux.
  • Example 2 The compound A (200 mg) obtained in Example 1 was dissolved in butyl acetate (2 ml) with heating under reflux. Heptane (1.5 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II
  • Example 2-3-25 The compound A (200 mg) obtained in Example 1 was dissolved in anisole (2 ml) by heating at 110°C. Heptane (2 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (187 mg, yield 89%) of compound A as a white solid.
  • Example 2-3-26 The compound A (200 mg) obtained in Example 1 was dissolved in anisole (2 ml) by heating at 110°C. Heptane (2 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (187 mg, yield 89%) of compound A as a white solid.
  • Example 2-3-26 The compound A (200 mg) obtained in Example 1 was dissolved in anisole (2 ml) by heating at 110°C. Heptane (2 ml) was added dropwise and the mixture was stirred for 21 hr
  • Example 2-4 Production of crystal form II of the compound A Step 1
  • the compound (12 g, 27 mmol) obtained in Step 1 was 0 dissolved in methanol (64 ml) , 28% sodium methoxide methanol solution (52 ml, 256 mmol) was added, and the mixture was heated under reflux for 24 hr. The reaction mixture was allowed to cool to room temperature and filtered through Celite. The filtrate was concentrated under reduced pressure. The residue 5 was acidified by adding water (360 ml) and concentrated hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed successively with ' water and saturated brine and dried over sodium sulfate.
  • the compound (19 g, 42 mmol) obtained in Step 3 was dissolved in dimethylformamide (65 ml), imidazole (3.4 g, 49.9 mmol) and tert-butyldimethylsilyl chloride (7.2 g, 47.8 mmol) were added, and the mixture was stirred at room temperature for 1.5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate.
  • the crude product (30 g) obtained in Step 5 was dissolved in isopropanol (150 ml) , IN aqueous sodium hydroxide solution (300 ml, 300 mmol) was added, and the mixture was heated under reflux for 2.5 hr.
  • the reaction mixture was allowed to cool to room temperature, and the mixture was filtered through Celite.
  • the filtrate was acidified by adding concentrated hydrochloric acid, and the mixture was stirred at room temperature for 2 . hr.
  • the precipitated solid was collected by filtration and vacuum dried to give a crude product (18 g) as a beige solid.
  • the obtained crude product (18 g) was suspended in butyl acetate (90 ml) , and subjected to slurry stirring with heating under reflux for 1 hr.
  • the obtained residue was dissolved in dimethylformamide (80 ml) , potassium carbonate (19 g, 137 mmol) was added, and the mixture was stirred with heating at 60°C for 1.5 hr. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. Water (250 ml) was added to the obtained residue and the mixture was stirred at room temperature for 30 min. The precipitated solid was collected by filtration.
  • the compound (22 g, 48 mmol) obtained in Step 3 was dissolved in dimethylformamide (60 ml), imidazole (3.9 g, 57.7 mmol) and tert-butyldimethylsilyl chloride (8.0 g, 53.0 mmol) were added, and the mixture was stirred at room temperature for 1.5 hr.
  • the reaction mixture was concentrated under reduced pressure, and the obtained residue was dissolved in ethyl acetate (200 ml) , washed successively with water (twice) and saturated brine, and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure.
  • reaction mixture was allowed to cool to room temperature, ethyl acetate (200 ml) was added, washed successively with IN hydrochloric acid, water, saturated aqueous sodium hydrogen carbonate, water and saturated brine, and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure.
  • Example 3 Production of crystal form III of the compound A
  • Example 3-1 Production of crystal form III of the compound A
  • the crystal form II of compound A (10.0 g, 22.3 mmol) obtained in Example 2-2 was added to isobutyl acetate (30 mL) and the crystal was dissolved by heating under reflux. The solution was cooled to 90°C, and stirred for 5 hr to allow precipitation of crystals. This solution was further allowed to cool to room temperature, and further stirred for 12 hr. The precipitated crystal was collected by filtration. The obtained crystal was washed with isobutyl acetate (10 mL) and vacuum dried to give a white crystal (9.85 g, yield 98.5%) . Since this crystal was confirmed to be different from crystal form II by XRPD analysis, a crystal showing the XRPD chart (Fig. 1) as this crystal was taken as crystal form III.
  • Example 3-2 Production of crystal form III of the compound A
  • the crystal form II of compound A (250 g, 558 mmol) obtained in Example 2-2 was added to isobutyl acetate (750 mL) .
  • a seed crystal (12.5 g) of the crystal form III of compound A obtained in Example 3 was added at room temperature and the mixture was stirred for 17 hr. The precipitated crystal was collected by filtration.
  • the obtained crystal was washed with isobutyl acetate (250 mL) , and vacuum dried to give the object product (crystal form III, 259 g, yield 98.6%) as a white crystal.
  • This crystal was confirmed to be equivalent to the standard product of the crystal (crystal form III of compound A obtained in Example 3-1) by XRPD analysis.
  • Example 3-3 Production of crystal form III of the compound A Compound A (crystal form II, 10.0 g, 22.3 mmol) obtained in Example 2-2 was added to isopropanol (30 mL) , and the mixture was heated under reflux to dissolve the crystal. The solution was cooled to 70°C, a seed crystal (10 mg) of the crystal form III of compound A obtained in Example 3-1 was added, and the mixture was stirred .for 5 hr. This mixture was further allowed to cool to room temperature, stirred for 12 hr, and the crystal was collected by filtration.
  • Example 3-4 Production of crystal form III of compound A
  • the crystal form II of compound A (7.00 g, 15.6 mmol) obtained in Example 2-2 was added to a mixed solution of ethanol (52.5 mL) and water (7 mL) and dissolved by heating. Water (28 mL) was added, a seed crystal (10 mg) of the object product was added at 70°C and the mixture was stirred for 4 hrs. After allowing to cool to room temperature, the mixture was ice-cooled and further stirred for 2 hrs , and the crystals were collected by filtration. The obtained crystals were washed with a mixed solution of cool ethanol (8.4 mL) and water (5.6 mL) and vacuum dried to give the object product as white crystals (crystal form III, 6.77 g, yield 96.8%). This crystal was confirmed to be equivalent to the standard product (Example 3-1) by XRPD analysis.
  • the aforementioned crystal (crystal form I) obtained in Reference Example 1 the crystal (crystal form II) obtained in Example 1 and the crystal (crystal form III) obtained in Example 3-1 were used as samples.
  • Analysis test 1 X-ray powder diffractometry This test aims at obtaining X-ray powder diffraction patterns to specify the crystal form of the crystals obtained in Reference Example 1 , Example 1 and Example 3-1. The diffraction patterns are utilized to specify the crystal form, evaluate the stability, to determine the purity and the like.
  • a sample was fixed to an aluminum cell, and the measurement was performed using an X-ray powder diffractometer (RINT 2000/PC Ultima "1" , manufactured by Rigaku Corporation, X-ray source: Cu-K( ⁇ l ray, tube voltage: 40 kV, tube electric current: 40 mA, scan speed: 5° per min, step width: 0.02°, diffraction angle: 5-40°) , based on which the diffraction patterns were obtained.
  • the obtained diffraction patterns are shown in Fig. 1.
  • Example 1 Example 1 and Example 3-1 were distinct from each other, and show characteristic diffraction patterns as shown in the X-ray powder diffraction pattern. Therefore, in the present specification, they were named as crystal form I, crystal form II and crystal form III, based on these X-ray powder diffraction patterns.
  • the diffraction peak characteristic of each crystal may be evaluated in a comprehensive manner based on the diffraction chart in Fig. 1.
  • the main diffraction peaks and characteristic diffraction peaks specified from the diffraction patterns in Fig. 1 are shown below.
  • Main diffraction peak:2 ⁇ 6.58, 14.40, 14.64, 15.24, 16.48, 19.16, 20.90, 21.14, 22.24, 24.74, 25.64, 26.12, 27.20°;
  • Main diffraction peak:2 ⁇ 8.54, 14.02, 15.68, 15.90, 16.00, 17.06, 17.24, 17.84, 18.12, 19.50, 19.90, 22.26, 22.68, 23.02, 24.16,
  • DSC Differential Scanning Calorimetry
  • Crystal form I and crystal form II were subjected to measurement using a Differential Scanning Calorimetry (DSC) measurement apparatus (DSC8240, manufactured by Rigaku Corporation) , under atmosphere, measurement sample 5+1 mg, temperature rise rate: 10°C/min, aluminum open pan, and alumina oxide as a reference. The enthalpy and extrapolated onset temperature at an endothermic peak on the obtained DSC curve were determined.
  • DSC Differential Scanning Calorimetry
  • Crystal form III was subjected to measurement using a DSC measurement apparatus (DSC8240, manufactured by Rigaku
  • crystal form III shows greatest enthalpy and highest extrapolated onset temperature among three crystal forms. Thus, crystal form III was confirmed to be most stable form. 3. Purity test This test aims at measurement of the purity of compound A. The purity can be used as indices of chemical stability. 3.1. Purity of compound of crystal form I and crystal form II
  • Each sample (crystal form I and crystal form II, ca. 10 5 mg) was dissolved in acetonitrile to make an amount of 10 mL and used as a sample solution.
  • This solution (10 ⁇ L) was applied to high performance liquid chromatography (HPLC) under the following conditions.
  • HPLC high performance liquid chromatography
  • the peak area of each sample solution was measured by automatic integration, and the purity was determined 0 by the following formula. The purity is shown in the Tables 5 and 6 below.
  • Solubility test This test aims at measurement of solubility of the crystal in various test solutions and under various pHs.
  • the solubility is one of the indices of the stability of the above-mentioned crystal form I, crystal form II and crystal form III and can be used also as a reference indices of absorbability of crystal form by living organisms .
  • Each sample (crystal form I type I, crystal form II and crystal form III, ca. 10 mg) was placed in a 10 mL centrifuge tube together with the following test solution (5 mL) and shaken with a shaker (SR-1M; manufactured by Tietech Co., Ltd.) for 14 hours. After shaking, the mixture was centrifuged (3000 rpm, 20 min) and the supernatant was filtered through 0.2 ⁇ m pore size - 13 mm diameter polytetrafluoroethylene disk filter (Millex-LG; manufactured by Millipore Corporation) . The measurement was performed by high performance liquid chromatography (HPLC) . The results are shown in Table 4.
  • Mcllvaine buffer obtained by mixing disodium hydrogenphosphate and citric acid at a given ratio to adjust to a given pH.
  • crystal form I was unstable but crystal form II and crystal form III were extremely stable under various preservation conditions. Therefore, it was evidenced that crystal form II and crystal form III are preferable for use as a pharmaceutical product and the like.
  • crystal form II is more preferable, and crystal form III is more preferable because it is the most stable crystal.
  • Escherichia coli recombinant BL21(DE3) transformed with plasmid pET21a-IN-Fl85H obtained in (i) was shake cultured at 30°C in a liquid medium containing ampicillin. When the culture reached the logarithmic growth phase, isopropyl- ⁇ -D- thiogalactopyranoside was added to promote expression of integrase gene. The culture was continued for 3 hr to promote accumulation of the integrase protein. The recombinant E. coli was collected in pellets by centrifugal separation and preserved at -80°C. The E.
  • Lysis buffer (20 mM HEPES (pH 7.5), 5 mM DTT, 10 mM CHAPS, 10% glycerol) containing IM sodium chloride and subjected to repeat pressurization and depressurization for rupture, and centrifugal separation at 4°C, 40,000 ⁇ g, 60 min to recover a water-soluble fraction (supernatant) .
  • Lysis buffer 20 mM HEPES (pH 7.5), 5 mM DTT, 10 mM CHAPS, 10% glycerol
  • the eluted integrase protein solution was applied to a
  • Superdex 75 (Pharmacia Corporation) column for gel filtration. The protein was eluted with Lysis buffer containing IM sodium chloride .
  • the obtained fractions of the integrase protein were collected and preserved at -80°C.
  • TE buffer (10 mM Tris-hydrochloric acid (pH 8.0), 1 mM EDTA) and mixed with donor DNA, target DNA, and each complementary strand
  • (+ and - strands) to 1 ⁇ M.
  • the mixture was heated at 95°C for 5 min, 80°C for 10 min, 70°C for 10 min, 60°C for 10 min, 50°C for 10 min and 40°C for 10 min and preserved at 25°C to give a double stranded DNA, which was used for the test.
  • Donor DNA (- strand having biotin attached to the 5' terminal)
  • Donor + strand 5 '-Biotin-ACC CTT TTA GTC AGT GTG GAA AAT CTC
  • Target DNA (+, - strands both having digoxigenin added at 3' terminal
  • Target + strand 5'-TGA CCA AGG GCT AAT TCA CT-Dig-3 ' (SEQ ID NO: 3)
  • Target - strand 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID NO: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID NO: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID NO: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID NO: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID NO: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID NO: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID NO: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID NO: 5'-AGT GAA TTA GCC CTT GGT CA-
  • reaction mixture 70 ⁇ l, see the following * for the composition
  • test substance 10 ⁇ l
  • 100 ⁇ g/ml integrase protein 10 ⁇ l
  • a peroxidase color solution (manufactured by Bio Rad, 100 ⁇ l) was added and allowed to react at room temperature for 4 min. The color reaction was stopped by adding IN sulfuric acid (100 ⁇ l) . The absorbance at 450 nm was measured.
  • the HIV integrase inhibitory activity (IC 50 ) of the compound A of the present invention was calculated from the inhibition rate according to the following formula. The results are shown in Table 8.
  • Inhibition rate (%) [1- (Object-Blank) / (Control-Blank) ] X 100
  • composition of the reaction mixture 30 mM morpholinopropanesulfonic acid (MOPS) , 5 mM MgCl 2 , 3 mM dithiothreithol (DTT) , 0.1 mg/mL bovine serum albumin (BSA) , 5% glycerol, 10% dimethyl sulfoxide (DMSO), 0.01% Tween 20
  • MOPS morpholinopropanesulfonic acid
  • DTT dithiothreithol
  • BSA bovine serum albumin
  • DMSO dimethyl sulfoxide
  • nucleoside reverse transcriptase inhibitors zidovudine, lamivudine, tenofovir
  • non-nucleoside reverse transcriptase inhibitors efavirenz
  • protease inhibitors infected with HIV-1 IIIB
  • IC 50 and CC 50 of each pharmaceutical agent alone are measured prior to the combined use test. 5 concentrations of pharmaceutical agent a and 9 concentrations of pharmaceutical agent b, determined based on these results, are combined to evaluate the effect of combined use of two agents . For combined use of three agents, a high concentration pharmaceutical agent b and a pharmaceutical agent c are mixed and pharmaceutical agent a and the concentration are combined for evaluation.
  • test results of the crystal or mixed crystal of compound A and combination drug alone or in combination thereof are analyzed based on the programs of Prichard and Shipman MacSynergy II version 2.01 and Deltagraph version 1.5d.
  • a three-dimensional plot is drawn from % inhibition at the concentrations of each combined pharmaceutical agent, obtained from 3 times of tests, with 95% (or 68%, 99%) confidence limits , and the effect of the combined use is evaluated based on the numerical values of ⁇ M 2 % calculated therefrom.
  • the criteria of evaluation are shown in the following.
  • the crystal of compound A of the present invention which has the above-mentioned particular crystal form, shows an anti- HIV effect as well as superior crystal stability. Therefore, it is useful as a starting material of a pharmaceutical composition, particularly, various pharmaceutical compositions for the prophylaxis and/or treatment of AIDS.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides a crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, which shows a particular powder X-ray diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ (°) as measured by powder X-ray diffractometry. The crystal of the present invention is superior in physical and chemical stability.

Description

DESCRIPTION
STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND
TECHNICAL FIELD
The present invention relates to a stable crystal of 6- (3- chloro-2-fluorobenzyl) -1- [ (S) -l-hydroxymethyl-2-methylpropyl] -7- methoxy-4-oxo-l , 4-dihydroquinoline-3-carboxylic acid
Figure imgf000003_0001
(hereinafter sometimes to be compound A) and a mixed crystal thereof. The present invention also relates to a pharmaceutical composition comprising the crystal or the mixed crystal.
BACKGROUND OF THE ART The present Applicant has disclosed in Japanese Patent Application No. 2003-293117 filed by the same Applicant that the above-mentioned compound A has an inhibitory action on integrase that is an en essential enzyme for the growth of HIV (Human Immunodeficiency Virus) , which is a causative virus of AIDS (Acquired Immunodeficiency Syndrome) , and shows an anti-HIV effect (particularly Example 4-32 and Experimental Example) . In general, when a compound is used as a pharmaceutical product, chemical and physical stability of the compound is required so as to maintain quality and/or facilitate preservation. Not only the final pharmaceutical composition but also a compound as a synthetic starting material is desirably chemically and physically stable for the same reasons. Therefore, such compound is preferably a crystal, particularly preferably a stable crystal. When the compound has crystal polymorphism, the most stable crystal is generally selected. While the above-mentioned application describes compound A, no concrete description relating to the crystal form of compound A is found.
SUMMARY OF THE INVENTION Thus, the present inventors have studied various crystal forms of compound A in an attempt to find a stable crystal of compound A. As a result, they have found that compound A has crystal polymorphism, and a crystal of compound A having a particular crystal form is useful as a stable crystal, and based on which findings, they have completed the present invention.
Accordingly, the present invention provides the following. [1] A crystal (crystal form II) of 6- (3-chloro-2-fluorobenzyl) - 1- [ (S) -l-hydroxymethyl-2-methylpropyl] -7-methoxy-4-oxo-l , 4- dihydroquinoline-3-carboxylic acid, which has an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2θ(°) of 6.56, 13.20, 19.86, 20.84, 21.22, 25.22° as measured by X-ray powder diffractometer; [2] a crystal (crystal form III) of 6- (3-chloro-2-fluorobenzyl) - 1- t (S) -l-hydroxymethyl-2-methylpropyl] -7-methoxy-4-oxo-l ,4- dihydroquinoline-3-carboxylic acid, which has an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2θ(°) of 8.54, 14.02, 15.68, 17.06, 17.24, 24.16, 25.74° as measured by X-ray powder diffractometer; [3] a crystal (crystal form III) of 6- (3-chloro-2-fluorobenzyl) - 1- [ (S) -l-hydroxymethyl-2-methylpropyl] -7-methoxy-4-oxo-l , 4- dihydroquinoline-3-carboxylic acid, having an extrapolated onset temperature of 162.1+5.0°C;
[4] the crystal of any of the above-mentioned [1] to [3] , which has a purity of crystal of not less than 70%; [5] a mixed crystal comprising the crystal of the above- mentioned 1 and the crystal of the above-mentioned [2] or [3] ; [6] the mixed crystal of the above-mentioned [5] , wherein the purity of crystal is not less than 70%; [7] a pharmaceutical composition comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above-mentioned [5] or [6] , and a pharmaceutically acceptable carrier;
[8] an integrase inhibitor comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above- mentioned [5] or [6] as an active ingredient; [9] an antivirus agent comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above- mentioned [5] or [6] as an active ingredient; [10] an anti-HIV agent comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above- mentioned [5] or [6] as an active ingredient; [11] an anti-HIV composition comprising the crystal of any of the above-mentioned [1] to [4] or the mixed crystal of the above-mentioned [5] or [6] and, one or more kinds of other anti- HIV active substances as active ingredients; and [12] an anti-HIV agent for a multiple drug therapy with other anti-HIV agent, which comprises the crystal of any of the above- mentioned [1] to [4] or the mixed crystal of the above-mentioned [5] or [6] as an active ingredient.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows multiple records of X-ray powder diffraction patterns, wherein the upper line shows the diffraction pattern of crystal form III, the middle line shows the diffraction pattern of crystal form I, the lower line shows the diffraction pattern of crystal form II, the vertical axis shows diffraction intensity (cps: counts per second: intervals of scale is 2500 cps) and the transverse axis shows diffraction angle 2Θ(°).
Fig. 2 shows multiple records of X-ray powder diffraction pattern obtained from the sample after 3-day preservation of the stability test of crystal form I. For comparison, the uppermost line shows the diffraction pattern (initial conditions) of crystal form II, and the lowermost line shows the diffraction pattern (initial conditions) of crystal form I. Shown from the second line are diffraction patterns under preservation condition #6 (60°C/75% R.H. , open container, 3 weeks preservation) , preservation condition #4 (60°C, container with stopper, 3 weeks preservation) , preservation condition #5 (60°C, open container, 3 weeks preservation) , preservation condition #3 (80°C, open container, 3 days preservation) and preservation condition #2 (80°C, container with stopper, 3 days preservation) . The vertical axis shows diffraction intensity (cps: counts per second: intervals of scale is 2500 cps) and the transverse axis shows diffraction angle 2Θ (°) •
EFFECT OF THE INVENTION The crystal or mixed crystal of compound A of the present invention has the above-mentioned particular crystal form and is superior in physical and chemical stability, which in turn has advantage that maintenance of the quality of compound A for a long-term becomes possible, which facilitates preservation. In addition, they have advantage that handling during production of various pharmaceutical compositions and bulk is easy, which reduces the production cost. DETAILED DESCRIPTION OF THE INVENTION
The present invention is explained in detail in the following.
In the present invention, the "crystal form II" of compound A means a crystal of compound A, which has an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2Θ(°) of 6.56, 13.20, 19.86, 20.84, 21.22, 25.22° as measured by X-ray powder diffractometer.
In the present invention, the "crystal form III" of compound A means a crystal of compound A, which has an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2Θ (°) of 8.54, 14.02, 15.68, 17.06, 17.24, 24.16, 25.74° as measured by X-ray powder diffractometer.
The diffraction peak value at the above-mentioned diffraction angle 20 (°) may show slight measurement error due to the measurement instruments or measurement conditions and the like. To be specific, the measurement error may be within the range of ±0.2, preferably +0.1, more preferably ±0.06.
The crystal of compound A of the present invention is also characterized by thermal analysis. For example, when the crystal form III of compound A of the present invention is subjected to Differential Scanning Calorimetry (DSC) , the enthalpy of endothermic peak is about 81 J/g, and extrapolated onset temperature is 162.1±5.0°C, preferably 162.1±3.0°C, more preferably 162.1±1.0°C, wherein the "extrapolated onset temperature" means, as defined by JIS K 7121 (measurement method of transfer temperature of plastic) , the temperature at an intersection of the extrapolated baseline of the lower temperature side toward the higher temperature side with the tangent line drawn at the point showing the greatest slope on the leading edge of the melting peak on a lower temperature side in a DSC curve. When the enthalpy and extrapolated onset temperature of the endothermic peak is within the above- mentioned range, the crystal of compound A is stable. The crystal of compound A of the present invention may be either a crystal form II or a crystal form III, or a mixed crystal of a crystal form II and a crystal form III. For use in a pharmaceutical product of compound A and the like, the crystal form II or crystal form III is preferable because they are stable crystals, and a crystal form III is more preferable because it is the most stable crystal. In addition, a crystal form II is preferable in view of the absorbability by living organisms upon administration as a pharmaceutical composition. In the present invention, the "purity of crystal" means the purity of the crystal form II or crystal form III of compound A. In the case of a mixed crystal of a crystal form II and a crystal form III, it means the ratio of crystal relative to the total amount of substance of a crystal form II and a crystal form III. The purity of the crystal of the present invention can be determined by, for example, known methods such asX-ray powder diffractometry, thermal analysis and the like. The purity of the crystal or mixed crystal of the present invention does not need to be 100%, and may be not less than 70%, preferably not less than 80%, more preferably not less than 90%, more preferably not less than 95%, and most preferably not less than 98%. Purity within this range is preferable for guaranteeing the quality.
The crystal or mixed crystal of compound A of the present invention can be administered to a mammal (human, mouse, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey etc.) and the like as various pharmaceutical compositions such as anti-HIV agents , HIV integrase inhibitors , antivirus agents and the like used for, for example, the prophylaxis and/or treatment of AIDS. When the crystal or mixed crystal of compound A of the present invention is used as a pharmaceutical composition, it is admixed with pharmaceutically acceptable carriers, excipients, diluents , extending agents , disintegrants , stabilizers , preservatives, buffers, emulsifiers, flavoring agents, coloring agents, sweetening agents, thickeners, correctives, dissolution aids , and other additives , that are generally known per se , such as water, vegetable oil, alcohol (e.g., ethanol or benzyl alcohol etc.), polyethylene glycol, glycerol triacetate, gelatin, carbohydrate (e.g., lactose, starch etc.), magnesium stearate, talc, lanolin, petrolatum and the like, formed into tablet, pill, powder, granule, suppository, injection, eye drop, liquid, capsule, troche, aerosol, elixir, suspension, emulsion, syrup and the like by a conventional method, and administered systemically or topically, and orally or parenterally. While the. dose varies depending on age, body weight, symptom, treatment effect, administration method and the like, it is generally 0.01 mg to 1 g per administration for an adult, which is- given once to several times a day orally or in a dosage form of an inj ction such as intravenous injection and the like. An anti-HIV agent is generally required to sustain its effect for a long time, so that it can be effective not only for temporal suppression of viral growth but also for the prohibition of viral re-growth. This means that a prolonged administration is necessary and that a high single dose may be frequently inevitable to sustain the effect for a longer period during night and the like. Such prolonged and high dose administration increases the risk of side effects.
In view of this, one of the preferable modes of the present invention is such compound permitting high absorption by oral administration, and such compound capable of maintaining blood concentration of the administered compound for an extended period of time.
By the "prophylaxis of AIDS" is meant, for example, administration of a pharmaceutical agent to an individual who tested HIV positive but has not yet developed the disease state of AIDS, administration of a pharmaceutical agent to an individual who shows an improved disease state of AIDS after treatment but who carries HIV still to be eradicated and whose relapse of AIDS is worried, and administration of a pharmaceutical agent out of a fear of possible infection.
The anti-HIV composition of the present invention is used for, for example, a multiple drug combination therapy of AIDS. Examples of the "other anti-HIV active substance" to be used for the anti-HIV composition include an anti-HIV antibody, an HIV vaccine, immunostimulants such as interferon and the like, an HIV ribozyme, an HIV antisense drug, an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, an inhibitor of bond between a bond receptor (CD4, CXCR4, CCR5 and the like) of a host cell recognized by virus and the virus, and the like. Specific examples of the HIV reverse transcriptase inhibitor include Retrovir(R) (zidovudine) , Epivir(R) (lamivudine) , Zerit(R) (sanilvudine) , Videx(R) (didanosine) , Hivid(R) (zalcitabine) , Ziagen(R) (abacavir sulfate) , Viramune (R) (nevirapine) , Stocrin(R) (efavirenz) , Rescriptor (R) (delavirdine mesylate) , Combivir (R) (zidovudine+lamivudine) , Trizivir (R) (abacavir sulfate+lamivudine+zidovudine) , Coactinon(R) (emivirine) , Phosphonovir (R) , Coviracil (R) , alovudine (3 '-fluoro-3 '-deoxythymidine) , Thiovir (thiophosphonoformic acid), Capravirin (5- [(3,5- dichlorophenyl) thio] -4-isopropyl-l- (4-pyridylmethyl) imidazole-2- methanol carbamic acid), Tenofovir disoproxil fumarate ((R)-[[2- (6-amino-9H-purin-9-yl) -1-methylethoxy]methyl] phosphonic acid bis (isopropoxycarbonyloxymethyl) ester fumarate), DPC-083 ((4S)- 6-chloro-4-[ (IE) -cyclopropylethenyl]-3 , 4-dihydro-4- trifluoromethyl-2 (IH) -quinazolinone) , DPC-961 ( (4S) -6-chloro-4- (cyclopropylethynyl) -3 ,4-dihydro-4- (trifluoromethyl) -2 (IH) - quinazolinone), DAPD ( (-) -β-D-2 ,6-diaminopurine dioxolane) , Immunocal, MSK-055, MSA-254, MSH-143, NV-01, TMC-120, DPC-817, GS-7340, TMC-125, SPD-754, D-A4FC, capravirine, UC-781, emtricitabine, alovudine, Phosphazid, UC-781, BCH-10618, DPC- 083, Etravirine, BCH-13520, MIV-210, Abacavir sulfate/lamivudine, GS-7340, GW-5634, GW-695634 and the like, wherein (R) means a registered trademark (hereinafter the same) and the names of other pharmaceutical agents are general names.
Specific examples of the HIV protease inhibitor include Crixivan(R) (indinavir sulfate ethanolate) , saquinavir, Invirase (R) (saquinavir mesylate), Norvir(R) (ritonavir) , Viracept(R) (nelfinavir mesylate), lopinavir, Prozei (R) (amprenavir) , Kaletra(R) (ritonavir+lopinavir) , mozenavir dimesylate ( [4R- (4α,5α,6β) ]-l,3-bis[ (3-aminophenyl)methyl]- hexahydro-5 , 6-dihydroxy-4 , 7-bis (phenylmethyl) -2H-1 , 3-diazepin-2- one dimethanesulfonate) , tipranavir (3 '-[ (1R) -l-[ (6R) -5,6- dihydro-4-hydroxy-2-oxo-6-phenylethyl-6-propyl-2H-pyran-3- yl] propyl] -5- (trifluoromethyl) -2-pyridinesulfonamide) , lasinavir (N- [5 (S) - (tert-butoxycarbonylamino) -4 (S) -hydroxy-6-phenyl-2 (R) - (2,3, 4-trimethoxybenzyl) hexanoyl] -L-valine 2- methoxyethylenamide) , KNI-272 ( (R) -N-tert-butyl-3- [ (2S,3S) -2- hydroxy-3-N- [ (R) -2-N- (isoquinolin-5-yloxyacetyl) amino-3- methylthiopropanoyl] amino-4-phenylbutanoyl] -5 , 5-dimethyl-l , 3- thiazolidine-4-carboxamide) , GW-433908, TMC-126, DPC-681, buckminsterfullerene, MK-944A (MK944 (N- (2 (R) -hydroxy-1 (S) - indanyl) -2 (R) -phenylmethyl-4 (S) -hydroxy-5- [4- (2- benzo [b] furanylmethyl) -2 (S) - (tert-butylcarbamoyl) piperazin-1- yl]pentanamide) +indinavir sulfate), JE-2147 ( [2 (S) -oxo-4- phenylmethyl-3 (S) - [ (2-methyl-3-oxy) phenylcarbonylamino] -1- oxabutyl] -4- [ (2-methylphenyl) methylamino] carbonyl-4 (R) -5 , 5- dimethyl-l,3-thiazole) , BMS-232632 ( (3S,8S,9S,12S) -3 ,12-bis (1 , 1- dimethylethyl) -8-hydroxy-4 , ll-dioxo-9- (phenylmethyl) -6- [ [4- (2- pyridinyl) phenyl]methyl] -2 ,5,6 ,10,13- pentaazatetradecanedicarboxylic acid dimethyl ester) , DMP-850 ( (4R, 5S , 6S , 7R) -1- (3-amino-lH-indazol-5-ylmethyl) -4 , 7-dibenzyl~3- butyl-5,6-dihydroxyperhydro-l,3-diazepin-2-one) , DMP-851, RO- 0334649, Nar-DG-35, R-944, VX-385, TMC-114, Tipranavir, Fosamprenavir sodium, Fosamprenavir calcium, Darunavir, GW-0385, R-944, RO-033-4649, AG-1859 and the like.
The HIV integrase inhibitor is exemplified by S-1360, L- 870810 and the like, the DNA polymerase inhibitor or DNA synthesis inhibitor is exemplified by Foscavir(R), ACH-126443 (L-2' ,3 '-didehydro-dideoxy-5-fluorocytidine) , entecavir ( (IS ,3S , 4S) -9- [4-hydroxy-3- (hydroxymethyl) -2- methylenecyclopentyl]guanine) , calanolide A ([10R- (10α, Hβ, 12α) ] -11 , 12-dihydro-12-hydroxy-6 ,6,10, ll-tetramethyl-4- propyl-2H, 6H, lOH-benzo [1 ,2-b: 3 , 4-b ' : 5 , 6-b"] tripyran-2-one) , calanolide B, NSC-674447 (1,1 '-azobisformamide) , Iscador (viscum alubm extract) , Rubitecan and the like, the HIV antisense drug is exemplified by HGTV-43, GEM-92 and the like, the anti-HIV antibody or other antibody is exemplified by NM-01, PRO-367, KD- 247, Cytolin(R), TNX-355 (CD4 antibody), AGT-1 , PRO-140 (CCR5 antibody) , Anti-CTLA-4MAb and the like, the HIV vaccine or other vaccine Is exemplified by ALVAC(R) , AIDSVAX(R) , Remune (R) , HIVgp41 vaccine, HIVgpl20 vaccine, HIVgpl40 vaccine, HIVgpl60 vaccine, HIVpl7 vaccine, HIVp24 vaccine, HIVp55 vaccine, AlphaVax Vector System, canarypox gpl60 vaccine, AntiTat, MVA-F6 Nef vaccine, HIVrev vaccine, C4-V3 peptide, p2249f, VIR-201, HGP-30W, TBC-3B, PARTICLE-3B and the like, Antiferon (interferon-α vaccine) and the like, the interferon or interferon agonist is exemplified by Sumiferon (R) , MultiFeron (R) , interferon-τ, Reticulose, human leukocyte interferon α and the like, the CCR5 antagonist is exemplified by SCH-351125 and the like, the pharmaceutical agent acting on HIV p24 is exemplified by GPG-NH2 (glycyl-prolyl-glycinamide) and the like, the HIV fusion inhibitor is exemplified by FP-21399 (1,4-bis [3-[ (2,4- dichlorophenyl) carbonylamino] -2-oxo-5 , 8-disodium sulfonyl]naphthyl-2,5-dimethoxyphenyl-l,4-dihydrazone) , T-1249 , Synthetic Polymeric Construction No3 , pentafuside, FP-21399, PRO-542, Enfuvirtide and the like, the IL-2 agonist or antagonist is exemplified by interleukin-2 , Imunace (R) , Proleukin(R) , Multikine (R) , Ontak(R) and the like, the TNF-α antagonist is exemplified by Thalomid(R) (thalidomide) , Remicade (R) (infliximab) , curdlan sulfate, the α-glucosidase inhibitor is exemplified by Bucast(R) and the like, the purine nucleoside phosphorylase inhibitor is exemplified by peldesine (2-amino-4-oxo-3H,5H-7- [ (3-pyridyl)methyl]pyrrolo [3,2- d]pyrimidine) and the like, the apoptosis agonist or inhibitor is exemplified by Arkin Z (R) , Panavir (R) , Coenzyme Q10 (2- deca (3-methyl-2-butenylene) -5 , 6-dimethoxy-3-methyl-p- benzoquinone) and the like, the cholinesterase inhibitor is exemplified by Cognex(R) and the like, and the immunomodulator is exemplified by Imunox(R), Prokine (R) , Met-enkephalin (6-de-L- arginine-7-de-L-arginine-8-de-L-valinamide-adrenorphin) , WF-10 (10-fold dilute tetrachlorodecaoxide solution) , Perthon, PRO-542, SCH-D, UK-427857, AMD-070, AK-602 and the like.
In addition, Neurotropin (R) , Lidakol (R) , Ancer 20 (R) , Ampligen(R) , Anticort(R), Inactivin(R) and the like, PRO-2000, Rev M10 gene, HIV specific cytotoxic T cell (CTL immunotherapy, ACTG protocol 080 therapy, CD4-ζ gene therapy) , SCA binding protein, RBC-CD4 complex, Motexafin gadolinium, GEM-92, CNI- 1493, (±)-FTC, Ushercell, D2S, BufferGel (R) , VivaGel (R) , Glyminox vaginal gel, sodium lauryl sulfate, 2F5, 2F5/2G12, VRX- 496, Ad5gag2, BG-777, IGIV-C, BILR-255 and the like are exemplified.
As the "other anti-HIV activity substance" to be used for the anti-HIV composition of the present invention in the multiple drug combination therapy, preferred are an HIV reverse transcriptase inhibitor and an HIV protease inhibitor. Two or three, or even a greater number of pharmaceutical agents can be used in combination, wherein a combination of pharmaceutical agents having different action mechanisms is one of the preferable embodiments. In addition, selection of pharmaceutical agents free of side effect duplication is preferable.
Specific examples of the combination of pharmaceutical agents include a combination of a group consisting of efavirenz , tenofovir, emtricitabine , indinavir, nelfinavir, atazanavir, ritonavir + indinavir, ritonavir + lopinavir and ritonavir + saquinavir, didanosine + lamivudine, zidovudine + didanosine, stavudine + didanosine, zidovudine + lamivudine, stavudine + lamivudine and emtriva, and the crystal or mixed crystal of the present invention (Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. August 13, 2001). Particularly preferred is a combined use of two agents of the crystal or mixed crystal of the present invention with efavirenz , indinavir, nelfinavir, tenofovir, emtricitabine, zidovudine or lamivudine, and a combined use of three agents of the crystal or mixed crystal of the present invention with zidovudine + lamivudine, tenofovir + lamivudine, tenofovir + zidovudine, tenofovir + efavirenz , tenofovir + nelfinavir, tenofovir + indinavir, tenofovir + emtricitabine, emtricitabine + lamivudine, emtricitabine + zidovudine, emtricitabine + efavirenz, emtricitabine + nelfinavir, emtricitabine + indinavir, nelfinavir + lamivudine, nelfinavir + zidovudine, nelfinavir + efavirenz, nelfinavir + indinavir, efavirenz + lamivudine, efavirenz + zidovudine or efavirenz + indinavir. The production method of the crystal or mixed crystal of compound A of the present invention is not particularly limited, and the crystal can be produced by a method known per se or methods shown in the following Examples and the like. Examples While the production method of the crystal of compound A of the present invention is explained in the following by referring to Examples , which are mere examples and do not limit the present invention in any way. Reference Example 1: Production of crystal form I of the compound A
Step 1
C0.H
& m
2,4-Difluorobenzoic acid (50 g, 316 mmol) was dissolved in concentrated sulfuric acid (200 ml) , and N-iodosuccinimide (68 g, 300 mmol) was added by portions at not more than 5°C. After the completion of the addition, the mixture was stirred at the same temperature for 4.5 hr. The reaction mixture was poured into ice water (ca. 600 ml) , then 10% aqueous sodium sulfite solution was added, and the mixture was stirred. The precipitated solid was collected by filtration, washed with water, and vacuum dried to give crude crystals (85 g) . The crude crystals obtained in the same manner were combined (total amount 205 g) , and recrystallized from 50% aqueous ethanol (820 ml) to give 2,4- difluoro-5-iodobenzoic acid (148 g, yield 73%) as a white solid. XH NMR(CDC13 300MHz) (σ) ppm: 6.94(1H, dd, J=10.3, 10.3Hz), 8.46 (IH, d, J=7.5Hz) Step 2
Figure imgf000015_0001
The compound (148 g, 521 mmol) obtained in Step 1 was dissolved in toluene (750 ml) , thionyl chloride (76 ml, 1.04 mol) and dimethylformamide (catalytic amount) were added, and the mixture was heated under reflux for 2 hr. The insoluble material was filtered off at 60°C, and the filtrate was concentrated under reduced pressure and azeotroped with toluene (330 ml) . The residue was dissolved in tetrahydrofuran (400 ml) , and this solution was added dropwise to a solution of ethyl 3,3- dimethylaminoacrylate (82 g, 573 mmol) and triethylamine (87 ml, 625 mmol) in tetrahydrofuran (400 ml) , and the mixture was heated under reflux for 7 hr. The reaction mixture was allowed to cool to room temperature, and concentrated under reduced pressure. Water (700 ml) and ethyl acetate (800 ml) were added for partitioning. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate (250 ml, X2) , water (300 ml) and saturated brine (300 ml) , and dried over sodium sulfate. After filtration of insoluble material, the filtrate was concentrated under reduced pressure to give a crude product (210 g) of 2- (2,4-difluoro-5-iodobenzoyl) -3- dimethylaminoacrylic acid ethyl ester as a brown solid. Step 3
Figure imgf000015_0002
The crude product (210 g) obtained in Step 2 was dissolved in tetrahydrofuran (500 ml), (S) - (+) -valinol (54 g, 521 mmol) was added, and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in dimethylformamide (600 ml) . Potassium carbonate (144 g, 1.04 mol) was added and the mixture was stirred with heating at 70°C for 2 hr. The reaction mixture was allowed to cool, and added to water (1500 ml) and stirred. The precipitated solid was collected by filtration and the obtained solid was washed successively with 30% aqueous ethanol (500 ml) and a mixed solvent of diethyl ether (150 ml) and hexane (150 ml) and vacuum dried to give 7- fluoro-1- ( (S) -l-hydroxymethyl-2-methylpropyl) -6-iodo-4-oxo-l , 4- dihydroquinoline-3-carboxylic acid ethyl ester (178 g, yield 76%) as a beige solid.
XH NMR(DMSO-d6 300MHz) (δ) ppm: 0.72(3H, d, J=6.6Hz), 1.10 (3H, d, J=6.6Hz), 1.28(3H, t, J=7.0Hz), 2.27 (IH, br) , 3.77 (IH, br) , 3.86(1H, br) , 4.23 (2H, q, J=7.0Hz), 4.56(1H, br) , 5.12 (IH, t, J=4.9Hz), 8.09 (IH, d, J=ll.lHz), 8.62 (IH, d, J=7.5Hz), 8.68 (IH, s)
MS (ESI) : M+ 448 Step 4
Figure imgf000016_0001
wherein TBDMS means a tert-butyldimethylsilyl group.
The compound (80 g, 179 mmol) obtained in Step 3 was dissolved in dimethylformamide (320 ml) , imidazole (16 g, 233 mmol) and tert-butyldimethylsilyl chloride (30 g, 197 mmol) were added, and the mixture was stirred at room temperature for 1.5 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed successively with saturated aqueous ammonium chloride solution and saturated brine, and dried over sodium sulfate. The organic layer was filtered and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate :hexane=l : 3 to 1:2) to give 1- ( (S) -l-tert-butyldimethylsilyloxymethyl-2-methylpropyl) -7- fluoro-6-iodo-4-oxo-l,4-dihydroquinoline-3-carboxylic acid ethyl ester (77 g, yield 77%) as a colorless amorphous form.
XH NMR(CDC13 400MHz) (δ) ppm: -0.07(3H, s) , -0.05(3H, s) , 0.77(9H, s) , 0.84(3H,d, J=6.5Hz), 1.18(3H, d, J=6.5Hz), 1.40(3H, t, J=7.2Hz), 2.35-2.50 (IH, m) , 3.85-3.95 (IH, m) , 3.98-4.10 (2H, m) , 4.30-4.40(2H, m) , 7.26(lH,s), 8.64(1H, s) , 8.94(1H, d, J=7.2Hz) MS (ESI) : M+ 562 Step 5
Figure imgf000017_0001
(Preparation of a solution of 3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran)
Under an argon stream, zinc powder (11 g, 267 mmol) was suspended in tetrahydrofuran (30 ml), 1 , 2-dibromoethane (0.15 ml, 1.8 mmol) and trimethylsilyl chloride (0.45 ml, 3.6 mmol) were added at 65°C, and the mixture was stirred with heating for 30 min. A solution of 3-chloro-2-fluorobenzyl bromide (41 g, 178 mmol) in tetrahydrofuran (100 ml) was added dropwise at 65°C, and the mixture was stirred with heating for 2 hr and allowed to cool to room temperature to give a solution of IM 3-chloro-2- fluorobenzylzinc bromide in tetrahydrofuran. This was used in the next main step. (Main step)
The compound (76 g, 136 mmol) obtained in Step 4 was dissolved in tetrahydrofuran (600 ml) and, under an argon stream, dibenzylidenacetonepalladium(II) (3.2 g, 5.5 mmol) and trifurylphosphine (2.6 g, 11.0 mmol) were added, and a solution of the aforementioned IM 3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran (178 ml, 178 mmol) was added dropwise at 60°C. After the completion of the dropwise addition, the mixture was stirred with heating at the same temperature for 2 hr. The reaction mixture was allowed to cool to room temperature, saturated aqueous ammonium chloride solution was added, and the mixture was filtered through celite. The filtrate was extracted twice with ethyl acetate. The organic layer was washed successively with water (twice) and saturated brine, and dried over magnesium sulfate. The organic layer was filtered and the filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (chloroform: acetone=40 : 1) to give 1- ( (S) -1-tert- butyldimethylsilyloxymethyl-2-methylpropyl) -6- (3-chloro-2- fluorobenzyl) -7-fluoro-4-oxo-l , 4-dihydroquinoline-3-carboxylic acid ethyl ester (68 g, yield 84%) as a colorless amorphous form. λE NMR(CDC13 400MHz) (δ) ppm: -0.09 (3H, s) , -0.05 (3H, s) , 0.75 (9H, s) , 0.85(3H,d, J=6.7Hz) , 1.18(3H, d, 6.7Hz) , 1.39(3H, t, J=7.1Hz) , 2.45(1H, br) , 3.89-3.92 (IH, m) , 3.98-4.02 (IH, m) , 4.07-4.12(lH, m) , 4.12(2H, s) , 4.34-4.41 (2H, m) , 6.96-7.00 (IH, m) , 7.03-7.05(lH, m) , 7.21-7.24 (IH, m) , 7.26-7.29 (IH, m) , 8.39(1H, d, J=8.8Hz) , 8.63(1H, s) Step 6
Figure imgf000018_0001
The compound (48 g, 86 mmol) obtained in Step 5 was dissolved in methanol (300 ml) , water (5 ml) and 28% sodium methoxide methanol solution (176 ml, 862 mmol) were added, and the mixture was heated under reflux for 24 hr. The reaction mixture was allowed to cool to room temperature and the mixture was neutralized by adding 6N hydrochloric acid. Methanol was evaporated under reduced pressure. Water was added to the obtained solution and the mixture was stirred. The precipitated solid was collected by filtration and the obtained solid was dissolved in ethyl acetate. The mixture was washed with water and dried over sodium sulfate. The solution was filtered and the filtrate was concentrated under reduced pressure. The obtained residue was recrystallized from ethyl acetate-hexane to give a compound (32 g, yield 86%) as a white solid. The obtained compound (32 g) was dissolved in butyl acetate (160 ml) by heating under reflux, and crystal form II was seeded at 75°C. The mixture was stirred for 3.5 hr while allowing to cool as it was. The precipitated solid was collected by filtration, washed with butyl acetate (25 ml) and vacuum dried to give a compound (25 g, yield 77%) as a white solid. The obtained compound (4.0 g) was dissolved in methanol (40 ml) by heating under reflux at 50°C, and added dropwise to water (40 ml) at room temperature. The mixture was stirred at room temperature for 16 hr, filtered, and the remaining solid was washed with 66% aqueous methanol, and vacuum dried to give a crystal of compound A (crystal form I) (3.9 g, yield 97%) as a white solid, m.p. 151-152°C
XH NMR (DMSO-de 300MHz) (δ) ppm: 0.72 (3H, d, J=6.5Hz), 1.16 (3H, d, J=6.5Hz), 2.30-2.50 (IH, m) , 3.70-3.90 (IH, m) , 3.90-4.00 (IH, m) , 4.03 (3H, s) , 4.12 (2H,s), 4.80-4.90 (IH, m) , 5.19 (IH, t) , 7.19-7.25 (2H, m) , 7.46-7.51 (2H, m) , 8.04 (IH, s) , 8.88 (IH, s) , 15.44 (IH, s) MS (ESI) : M+ 448
Example 1: Production of crystal form II of the compound A Step 1
Figure imgf000019_0001
2 ,4-Difluorobenzoic acid (50 g, 0.316 mmol) was dissolved in concentrated sulfuric acid (200 ml) , and N-iodosuccinimide (68 g, 300 mmol) was added by portions at not more than 5°C. After the completion of the addition, the mixture was stirred at the same temperature for 4.5 hr. The reaction mixture was poured into ice water (ca. 600 ml) , then 10% aqueous sodium sulfite solution was added, and the mixture was stirred. The precipitated solid was collected by filtration, washed with water, and vacuum dried to give crude crystals (85 g) . The crude crystals obtained in the same manner were combined (total amount 205 g) , and recrystallized from 50% aqueous ethanol (820 ml) to give 2,4-difluoro-5-iodobenzoic acid (148 g, yield 73%) as a white solid.
XH NMR(CDC13 300MHz) (σ) ppm: 6.94(1H, dd, J=10.3, 10.3Hz), 8.46 (IH, d, J=7.5Hz)
Step 2
Figure imgf000020_0001
The compound (148 g, 521 mmol) obtained in Step 1 was dissolved in toluene (750 ml), thionyl chloride (76 ml, 1.04 mol) and dimethylformamide (catalytic amount) were added, and the mixture was heated under reflux for 2 hr. The insoluble material was filtered off at 60°C, and the filtrate was concentrated under reduced pressure and azeoptoped with toluene (330 ml) . The residue was dissolved in tetrahydrofuran (400 ml) , and this solution was added dropwise to a solution of ethyl 3,3- dimethylaminoacrylate (82 g, 573 mmol) and triethylamine (87 ml, 625 mmol) in tetrahydrofuran (400 ml) , and the mixture was heated under reflux for 7 hr. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. Water (700 ml) and ethyl acetate (800 ml) were added to allow, partitioning. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate (250 ml) twice, water (300 ml) and saturated brine (300 ml) , and dried over sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (210 g) of 2- (2 ,4-difluoro-5-iodobenzoyl) -3- ' dimethylaminoacrylic acid ethyl ester as a brown solid. Step 3
Figure imgf000021_0001
The crude product (210 g) obtained in Step 2 was dissolved in tetrahydrofuran (500 ml), (S) - (+) -valinol (54 g, 0.521 mmol) was added, and the mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in dimethylformamide (600 ml). Potassium carbonate (144 g, 1.04 mol) was added, and the mixture was stirred with heating at 70°C for 2 hr. The reaction mixture was allowed to cool to room temperature, added to water (1500 ml) and the mixture was stirred. The precipitated solid was collected by filtration. The obtained solid was washed successively with 30% aqueous ethanol (500 ml) and a mixed solvent of diethyl ether (150 ml) and hexane (150 ml) , and vacuum dried to give 7-fluoro-1- ( (S) -l-hydroxymethyl-2- methylpropyl) -6-iodo-4-oxo-l , 4-dihydroquinoline-3-carboxylic acid ethyl ester (178 g, yield 76% (relative to Step 2) ) as a beige solid. XH NMR(DMSO-d6 300MHz) (δ) ppm: 0.72(3H, d, J=6.6Hz), 1.10 (3H, d, J=6.6Hz), 1.28 (3H, t, J=7.0Hz), 2.27 (IH, br) , 3.77 (IH, br) , 3.86(1H, br) , 4.23 (2H, q, J=7.0Hz), 4.56(1H, br) , 5.12 (IH, t, J=4.9Hz), 8.09 (IH, d, J=ll.lHz), 8.62 (IH, d, J=7.5Hz), 8.68 (IH, s) MS (ESI) : M+ 448 Step 4
Figure imgf000022_0001
The compound (150 g, 335 mmol) obtained in Step 3 was dissolved in dimethylformamide (500 ml), imidazole (30 g, 0.436 mmol) and tert-butyldimethylsilyl chloride (56 g, 369 mmol) were added, and the mixture was stirred at room temperature for 1.5 hr. Water was added to the reaction mixture and extracted with ethyl acetate. The organic layer was washed successively with water, saturated aqueous ammonium chloride solution and saturated brine, and dried over sodium sulfate. The organic layer was filtered and the filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (ethyl acetate: hexane=l : 3 to 1:2) to give 1- ( (S) -l-tert-butyldimethylsilyloxymethyl-2-methylpropyl) - 7-fluoro-6-iodo-4-oxo-l,4-dihydroquinoline-3-carboxylic acid ethyl ester (173 g, yield 92%) as a colorless amorphous form. XH NMR(CDC13 400MHz) (δ) ppm: -0.07(3H, s) , -0.05 (3H, ' s) , 0.77(9H, s) , 0.84(3H,d, J=6.5Hz), 1.18(3H, d, J=6.5Hz), 1.40(3H, t, J=7.2Hz), 2.35-2.50 (IH, m) , 3.85-3.95 (IH, m) , 3.98-4.10 (2H, m) , 4.30-4.40(2H, m) , 7.26(lH,s), 8.64(1H, s) , 8.94(1H, d, J=7.2Hz) MS (ESI) : M+ 562 Step 5
Figure imgf000022_0002
(Preparation of a solution of 3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran)
Under an argon stream, zinc powder (11 g, 175 mmol) was suspended in tetrahydrofuran (30 ml), 1,2-dibromoethane (0.1 ml, 1.20 mmol) and trimethylsilyl chloride (0.29 ml, 2.4 mmol) were added at 60°C, and the mixture was stirred with heating for 30 min. A solution of 3-chloro-2-fluorobenzyl bromide (27 g, 119 mmol) in tetrahydrofuran (60 ml) was added dropwise at 60°C. The mixture was stirred with heating for 1 hr and allowed to cool to room temperature to give a solution of IM 3-chloro-2- fluorobenzylzinc bromide in tetrahydrofuran. This was used in the next main step. (Main step)
The compound (50 g, 89 mmol) obtained in Step 4 was dissolved in tetrahydrofuran (400 ml) and, under an argon stream, dichlorobis (triphenylphosphine) palladium(II) (2.1 g, 3.6 mmol) was added and a solution of the above-mentioned IM 3-chloro-2- fluorobenzylzinc bromide in tetrahydrofuran was added dropwise at 60°C. After the completion of the dropwise addition, the mixture was stirred with heating at the same temperature for 1.5 hr. The reaction mixture was allowed to cool to room temperature, IN hydrochloric acid was added and the mixture was extracted 3 times with ethyl acetate. The organic layer was washed successively with water and saturated brine, and dried over magnesium sulfate. The organic layer was filtered and the filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (ethyl acetate :hexane=l : 2 to 1:1) to give 1- ( (S) -1-tert- butyldimethylsilyloxymethyl-2-methylpropyl) -6- (3-chloro-2- fluorobenzyl) -7-fluoro-4-oxo-l ,4-dihydroquinoline-3-carboxylic acid ethyl ester (43 g, yield 83%) as a brown amorphous form.
XH NMR(CDC13 400MHz) (δ) ppm: -0.09(3H, s) , -0.05(3H, s) , 0.75(9H, s) , 0.85(3H,d, J=6.7Hz), 1.18(3H, d, 6.7Hz), 1.39(3H, t, J=7.1Hz), 2.45(1H, br) , 3.89-3.92 (IH, m) , 3.98-4.02 (IH, m) , • 4.07-4.12(lH, m) , 4.12(2H, s) , 4.34-4.41 (2H, m) , 6.96-7.00 (IH, m) , 7.03-7.05(lH, m) , 7.21-7.24 (IH, m) , 7.26-7.29 (IH, m) , 8.39 (IH, d, J=8.8Hz), 8.63(1H, s) Step 6
Figure imgf000024_0001
The compound (43 g, 74 mmol) obtained in Step 5 was dissolved in methanol (280 ml) , 28% sodium methoxide methanol solution (151 ml, 742 mmol) and water (4.3 ml) were added, and the mixture was heated under reflux for 20 hr. The reaction mixture was filtered through celite. The filtrate was concentrated under reduced pressure. Water (400 ml) was added to the residue, and the mixture was washed with hexane (100 ml) . The aqueous layer was acidified by adding concentrated hydrochloric acid (65 ml) , and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, and dried over sodium sulfate. The solution was filtered and the filtrate was concentrated under reduced pressure. The obtained crude product (35 g, brown oil) was dissolved in ethyl acetate (49 ml) by heating under reflux, hexane (30 ml) was added while allowing to cool, and the mixture was stirred for 18.5 hr. The precipitated solid was collected by filtration, washed with a mixed solvent of ethyl acetate and hexane (1:1) , and vacuum dried to give a crystal of compound A (crystal form II) (27 g, yield 82%) as a white solid, m.p. 153.7-153.9°C XH NMR (DMS0-d6300MHz) (δ) ppm: 0.72 (3H, d, J=6.5Hz), 1.16 (3H, d, J=6.5Hz), 2.30-2.50 (IH, m) , 3.70-3.90 (IH, m) , 3.90-4.00 (IH, m) , 4.03 (3H, s) , 4.12 (2H,s), 4.80-4.90 (IH, m) , 5.19 (IH, t) , 7.19-7.25 (2H, m) , 7.46-7.51 (2H, m) , 8.04(1H, s) , 8.88 (IH, s) , 15.44 (IH, s) MS (ESI ) : M+ 448
Example 2: Production of crystal form II of the compound A Example 2-1: Production of crystal form II of the compound A Step 1
pjCc
Figure imgf000025_0001
2,4-Difluorobenzoic acid (100 g, 633 mmol) was dissolved in concentrated sulfuric acid (400 ml) , and N-iodosuccinimide (142 g, 601 mol) was added by portions at not more than 5°C. After the completion of the addition, the mixture was stirred at the same temperature for 6 hr. The reaction mixture was poured into ice water (ca. 2400 ml) , then saturated aqueous sodium sulfite solution was added, and the mixture was stirred. The precipitated solid was collected by filtration, washed with water, and vacuum dried to give crude crystals (188 g) . The crude crystals obtained in the same manner were combined (total amount 568 g) , and recrystallized from 50% aqueous ethanol (2600 ml) to give 2,4-difluoro-5-iodobenzoic acid (388 g, yield 68%) as a white solid.
XH NMR(CDC13 300MHz) (σ) ppm: 6.94(1H, dd, J=10.3, 10.3Hz), 8.46 (IH, d, J=7.5Hz)
Step 2
Figure imgf000025_0002
The compound (200 g, 704 mmol) obtained in Step 1 was dissolved in toluene (1000 ml) , thionyl chloride (103 ml, 408 mmol) and dimethylformamide (catalytic amount) were added, and the mixture was heated under reflux for 2 hr. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure and azeotroped with toluene. The residue was dissolved in tetrahydrofuran (500 ml) , this solution was added dropwise to a solution of ethyl 3,3-dimethylaminoacrylate (111 g, 775 mmol) and triethylamine (118 ml, 845 mmol) in tetrahydrofuran (500 ml) , and the mixture was heated under reflux for 3 hr. The reaction mixture was allowed to cool to room temperature and filtered and the filtrate was concentrated under reduced pressure. Water (500 ml) and ethyl acetate (800 ml) were added to allow partitioning. The organic layer was washed successively with saturated aqueous sodium hydrogen carbonate (200 ml) , water (200 ml) and saturated brine, and dried over sodium sulfate. The organic layer was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (273 g) of 2- (2 ,4-difluoro-5-iodobenzoyl) -3- dimethylaminoacrylic acid ethyl ester as a brown solid. Step 3
Figure imgf000026_0001
The crude product (273 g) obtained in Step 2 was dissolved in tetrahydrofuran (650 ml), (S) - (+) -valinol (73 g, 708 mmol) was added, and the mixture was stirred at room temperature for 2 hr. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in dimethylformamide (800 ml). Potassium carbonate (195 g 1.41 mol) was added, and the mixture was stirred with heating at 70°C for 2.5 hr. The reaction mixture was allowed to cool to room temperature, added to water (2000 ml) and the mixture was stirred. The precipitated solid was collected by filtration. The obtained solid was subject to slurry washing successively with water and 30% aqueous ethanol (650 ml) and vacuum dried to give a crude product (217 g) . The obtained crude product (217 g) was subject to slurry washing with a mixed solvent of ethyl acetate (650 ml) and hexane (440 ml) with heating under reflux. The mixture was filtered, and the remaining solid was vacuum dried to give 7- fluoro-1- ( (S) -l-hydroxymethyl-2-methylpropyl) -6-iodo-4-oxo-l ,4- dihydroquinoline-3-carboxylic acid ethyl ester (207 g, yield 66% (relative to Step 2) ) as a pale-brown solid.
^ NMR(DMSO-d6 300MHz) (δ) ppm: 0.72(3H, d, J=6.6Hz), 1.10 (3H, d, J=6.6Hz), 1.28 (3H, t, J=7.0Hz), 2.27 (IH, br) , 3.77 (IH, br) , 3.86(1H, br) , 4.23 (2H, q, J=7.0Hz), 4.56(1H, br) , 5.12 (IH, t, J=4.9Hz), 8.09 (IH, d, J=ll.lHz), 8.62 (IH, d, J=7.5Hz), 8.68 (IH, s)
MS (ESI) : M+ 448 Step 4
1 SOH I'SOTBDMS
The compound (150 g, 335 mmol) obtained in Step 3 was dissolved in dimethylformamide (450 ml) , imidazole (27 g, 397 mmol) and tert-butyldimethylsilyl chloride (58 g, 385 mmol) were added, and the mixture was stirred overnight at room' temperature. Water (900 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (680 ml) . The organic layer was washed successively with water (450 ml, 3 times) and saturated brine (200 ml) , and dried over sodium sulfate. The organic layer was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (192 g) of 1- ( (S) -l-tert-butyldimethylsilyloxymethyl-2-methylpropyl) -7- fluoro-6-iodo-4-oxo-l,4-dihydroquinoline-3-carboxylic acid ethyl ester as a pale-yellow amorphous form. Step 5
Figure imgf000028_0001
The crude product (162 g) obtained in Step 4 was dissolved in tetrahydrofuran (160 ml) and, under an argon stream, dibenzylidenacetone palladium (II) (1.7 g, 2.9 mmol) and trifurylphosphine (1.3 g, 5.8 mmol) were added. To this mixture was added dropwise at 60°C a solution of (375 ml, 375 mmol) of IM 3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran obtained in the same manner as in Example 1, Step 5 and, after the completion of the dropwise addition, the mixture was stirred with heating at the same temperature for 3.5 hr. The reaction mixture was allowed to cool to room temperature, ethyl acetate (640 ml) and 10% aqueous citric acid solution (400 ml) were added, and the mixture was filtered through Celite, and the filtrate was partitioned. The organic layer was washed successively with water (200 ml) , saturated aqueous sodium hydrogen carbonate (400 ml) and saturated brine (200 ml) , and dried over sodium sulfate. The organic layer was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (186 g) of 1- ( (S) -1-tert- butyldimethylsilyloxymethyl-2-methylpropyl) -6- (3-chloro-2- fluorobenzyl) -7-fluoro-4-oxo-l ,4-dihydroquinoline-3-carboxylic acid ethyl ester as a brown oil. Step 6
Figure imgf000028_0002
The crude product (193 g) obtained in Step 5 was dissolved in isopropanol (650 ml) , IN aqueous sodium hydroxide solution (1290 ml, 1.29 mol) was added, and the mixture was heated under reflux for 2 hr. The reaction mixture was allowed to cool to room temperature, and filtered through Celite. The filtrate was acidified by adding concentrated hydrochloric acid and the mixture was stirred. The precipitated solid was collected by filtration, and vacuum dried to give a crude product (132 g) as a pale-yellow solid. The crude products obtained in the same manner were combined (total amount 143 g) , suspended in butyl acetate (430 ml) and subject to slurry stirring with heating under reflux for 1 hr. The suspension was allowed to cool to room temperature and filtered and vacuum dried to give 6- (3- chloro-2-fluorobenzyl) -7-fluoro-1- ( (S) -l-hydroxymethyl-2- methylpropyl) -4-oxo-l , 4-dihydroquinoline-3-carboxylic acid (99 g, yield 74% (relative to Step 3) ) as a gray solid. XH NMR(DMS0-d6 400MHz) (δ) ppm: 0.71 (3H, d, J=6.5Hz), 1.13 (3H, d, J=6.5Hz), 2.36 (IH, br) , 3.77 (IH, br) , 3.94 (IH, br) , 4.25 (2H, s) , 4.77 (IH, br) , 5.16 (IH, t, J=2.4Hz), 7.19-7.23 (IH, m) , 7.32-7.35 (IH, m) , 7.48-7.52 (IH, m) , 8.24-8.28 (2H, ) , 9.00 (IH, s) , 15.00 (IH, s) MS (ESI) : M+ 436 Step 7
Figure imgf000029_0001
The compound (99 g, 227 mmmol) obtained in Step 6 was dissolved in methanol (530 ml) , 28% sodium methoxide methanol solution (465 ml, 2.28 mol) was added, and the mixture was heated under reflux for 20 hr. The reaction mixture was allowed to cool to room temperature and filtered through Celite. The filtrate- was concentrated under reduced pressure. The residue was acidified by adding water (200 ml) and concentrated hydrochloric acid (190 ml) , and extracted with ethyl acetate (500 ml) . The organic layer was washed twice with water (200 ml) , and dried over sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (108 g) . The obtained crude product (108 g) was dissolved in isobutyl acetate (330 ml) with heating and the mixture was stirred while allowing to cool for 24 hr. The precipitated solid was collected by filtration, and vacuum dried to give compound A (71 g, yield 69%) as a white solid. The crude crystals obtained in the same manner were combined (total amount 233 g) , dissolved in isobutyl acetate (470 ml) by heating under reflux, and the mixture was stirred overnight while allowing to cool. The precipitated solid was collected by filtration, and vacuum dried to give a crystal of compound A (crystal form II) (206 g, yield 88%) as a white solid.
1H NMR (DMSO-d6300MHz) (δ) ppm: 0.72 (3H, d, J=6.5Hz), 1.16 (3H, d, J=6.5Hz), 2.30-2.50 (IH, m) , 3.70-3.90 (IH, m) , 3.90-4.00 (IH, m) , 4.03 (3H, s) , 4.12 (2H, s) , 4.80-4.90 (IH, m) , 5.19 (IH, t) , 7.19-7.25 (2H, m) , 7.46-7.51 (2H, m) , 8.04 (IH, s) , 8.88 (IH, s) , 15.44 (IH, s)
MS (ESI) : M+ 448
Example 2-2: Production of crystal form II of the compound A
Step 1
Figure imgf000030_0001
5-Bromo-2,4-difluorobenzoic acid (82.7 kg, 349 mol) was dissolved in toluene (420 L) , thionyl chloride (62.3 kg, 523 mol) and dimethylformamide (catalytic amount) were added, and the mixture was stirred at 70°C for 6 hr. The reaction mixture was allowed to cool to room temperature, concentrated under reduced pressure, and azeotroped again with toluene (420 L) . The residue was dissolved in toluene (220 L) , this solution was added dropwise to a solution of ethyl 3 ,3-dimethylaminoacrylate (55.0 kg, 384 mol) and diisopropylethylamine (58.6 kg, 523 mol) in toluene (220 L) , and the mixture was stirred with heating at 70°C for 21 hr. The reaction mixture was allowed to cool to room temperature, (S) - (+) -valinol (36.0 kg, 349 mol) was added, and the mixture was stirred at room temperature for 1.5 hr. Water (420 L) was added to the reaction mixture to allow partitioning, and the organic layer was washed successively with IN hydrochloric acid (250 L, twice) , water (420 L) , 5% aqueous sodium hydrogen carbonate (250 L, twice) , water (420 L) and 10% brine (250 L) . The extract was concentrated under reduced pressure and azeotroped with dimethylformamide (420 L) to give a concentration residue (330 L) containing a crude product of 2- (5-bromo-2 ,4-difluorobenzoyl) -3- ( (S) -l-hydroxymethyl-2- methylpropylmethylamino) acrylic acid ethyl ester. Step 2
Figure imgf000031_0001
To a solution (330 L) of the crude product obtained in Step 1 in dimethylformamide was added 1,8- diazabicyclo [5.4.0]undecane (105 kg, 349 mol) and the mixture was stirred at room temperature for 23 hr. To the reaction mixture were added dimethylformamide (330 L) , and then water (170 L) and, after stirring for 2 hr, water (170 L) was added dropwise. The precipitated solid was collected by filtration and washed with dimethylformamide (170 L) -water (170 L) mixture, and then with ethanol (460 L) -water (200 L) mixed solution. The obtained solid was vacuum dried, suspended in an ethyl acetate (330 L) - n-heptane (330 L) mixture and subject to slurry washing. The suspension was filtered, and the remaining solid was vacuum dried to give 6-bromo-7-fluoro-1- ( (S) -1- hydroxymethyl-2-methylpropyl) -4-oxo-l ,4-dihydroquinoline-3- carboxylic acid ethyl ester (102 kg, yield 73%) as a yellow white solid. This compound was confirmed to be equivalent to the standard product of the compound by high performance liquid chromatography (HPLC) analysis. Step 3
Figure imgf000032_0001
The compound (45.0 kg, 112 mol) obtained in Step 2 and imidazole (9.95 kg, 146 mol) were suspended in toluene (180 L) , a solution of tert-butyldimethylsilyl chloride (17.8 kg, 118 mol) in toluene (45 L) was added at 50°C, and the mixture was stirred at the same temperature for 3 hr. Toluene (230 L) was added to the reaction mixture, and washed successively with water (450 L, twice) and 20% brine (450 L) . The extract was concentrated under reduced pressure and azeotroped with tetrahydrofuran (320 L) to give a concentration residue (390 L) containing a crude product of 6-bromo-l- ( (S) -1-tert- butyldimethylsilyloxymethyl-2-methylpropyl) -7-fluoro-4-oxo-l , 4- dihydroquinoline-3-carboxylic acid ethyl ester. Step 4
Figure imgf000032_0002
(Preparation of a solution of 3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran) Under a nitrogen stream, zinc powder (18.8 kg, 287 mol) was suspended in tetrahydrofuran (130 L) , 1 , 2-dibromoethane (470 g, 2.50 mol) was added at 60°C, and the mixture was stirred at the same temperature for 30 min. Trimethylsilyl chloride (560 g, 3.10 mol) was added to this suspension at room temperature, and the mixture was stirred with heating for 30 min. A solution of 3-chloro-2-fluorobenzyl bromide (54.0 kg, 242 mol) in tetrahydrofuran (65 L) was added dropwise at 0°C, and the mixture was stirred at 20°C for 3 hr. The remaining zinc was filtered off to give a solution of IM 3-chloro-2-fluorobenzylzinc bromide in tetrahydrofuran. This was used in the next main step. (Main step)
Under a nitrogen stream, tris (dibenzylidenacetone) dipalladium(O) (1.96 kg, 3.36 mol) and triphenylphosphine (1.77 kg, 6.72 mol) were dissolved in tetrahydrofuran (180 L) , and the mixture was stirred at room temperature for 1 hr. A solution (390 L) of the crude product obtained in Step 3 in tetrahydrofuran was added dropwise at room temperature and washed with tetrahydrofuran (45 L) . A solution (164 kg, 157 mol) of the above-mentioned IM 3-chloro-2- fluorobenzylzinc bromide in tetrahydrofuran prepared in advance was added dropwise at room temperature, and the mixture was stirred with heating at 55όC for 5 hr. The reaction mixture was allowed to cool to room temperature, toluene (230 L) and 25% aqueous ammonium chloride solution (230 L) were added and the mixture was stirred. After filtration, the mixture was partitioned. The organic layer was washed successively with 25% aqueous ammonium chloride solution (230 L) , water (230 L) , 5% aqueous sodium hydrogen carbonate (230 L, 3 times) and 10% brine (230 L) . The extract was concentrated under reduced pressure to give a crude product (80 L) of 6- (3-chloro-2-fluorobenzyl) -7- fluoro-1- ( (S) -l-hydroxymethyl-2-methylpropyl) -4-oxo-l , 4- dihydroquinoline-3-carboxylic acid as a brown oil. Step 5
The crude product (80 L) obtained in Step 4 was dissolved in isopropanol (180 L) , IN aqueous sodium hydroxide solution (180 L, 180 mol) was added, and the mixture was stirred with heating at 50°C for 9 hr. Activated carbon (4.5 kg) was added to the reaction mixture. The mixture was stirred at room temperature for 30 min, filtered through cellulose powder and thoroughly washed with an isopropanol (45 L) - water (45 L) mixture. Water (180 L) and n-heptane (230 L) were added to the filtrate and, after stirring, the mixture was partitioned. The aqueous layer was washed again with n-heptane (230 L) . 4N Hydrochloric acid (45 L, 180 mol) and methyl isopropyl ketone (450 L) were added to the organic layer and, after stirring, the mixture was partitioned. The organic layer was washed successively with 10% brine (230 L) , twice with 8.5% aqueous sodium hydrogen carbonate (230 L) , 0.5N hydrochloric acid (230 L) and water (230 L) . The extract was concentrated under reduced pressure, azeotroped 3 times with toluene (230 L) . The residue was stirred at 100°C for 1.5 hr, allowed to cool to room temperature and stirred for 3 hr. The precipitated solid was collected by filtration and the obtained solid was washed with toluene (45 L) and vacuum dried to give 6- (3-chloro-2- fluorobenzyl) -7-fluoro-1- [ (S) -l-hydroxymethyl-2-methylpropyl] -4- oxo-l,4-dihydroquinoline-3-carboxylic acid (42.5 kg, yield 87%) as a pale-yellow solid. This compound was confirmed to be equivalent to the standard product by HPLC analysis. Step 6
Figure imgf000034_0001
The compound (39.2 kg, 89.9 mol) obtained in Step 5 was dissolved in methanol (240 L) , 28% sodium methoxide methanol solution (173 kg, 899 mol) was added dropwise at 10°C, and the mixture was stirred with heating at 70°C for 21 hr. Activated carbon (3.9 kg) was added to the reaction mixture. The mixture was stirred at room temperature for 1 hr, filtered through cellulose powder and thoroughly washed with methanol (80 L) . Water (29 kg, 1620 mol) was added to the filtrate and the mixture was concentrated under reduced pressure. The residue was azeotroped twice with isopropanol (240 L, 120 L) . To the residue were added 15% brine (200 L) and toluene (200 L) and, after stirring, the mixture was partitioned. The organic layer was washed successively with 20% brine (200 L, 3 times) , 0.5N hydrochloric acid (200 L) containing sodium chloride (10 kg) and 20% brine (200 L) . The organic layer was concentrated under reduced pressure and azeotroped with ethyl acetate (200 L) . Ethyl acetate (320 L) and water (200 L) were added to the residue and, after stirring, the mixture was partitioned. The organic layer was concentrated under reduced pressure and azeotroped twice with isobutyl acetate (200 L) . The residue was dissolved by heating filtered while it was hot, and thoroughly washed with isobutyl acetate (20 L) . A seed crystal (crystal form II of compound A, 39 g) was added to the filtrate at 60°C, and the mixture was stirred at the same temperature for 1.5 hr. The mixture was stirred with heating at 80°C for 2 hr, allowed to cool to room temperature and further stirred for 6 hr The precipitated solid was collected by filtration. The obtained solid was washed with isobutyl acetate (40 L) and vacuum dried to give a crystal of compound A (crystal form II) (29.0 kg, yield 72%) as a white solid. This crystal was confirmed to be equivalent to the standard product of the crystal (crystal form II of compound A obtained in Example 2-1) by HPLC and X ray powder diffraction (XRPD) analysis . Example 2-3: Production of crystal form II of the compound A The crystal form II can be also produced by crystallization according to the methods described in Examples 2-3-1 to 2-3-26. Example 2-3-1
The compound A (200 mg) obtained in Example 1 was dissolved in 1-butanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (125 mg, yield 63%) of compound A as a white solid. Example 2-3-2
The compound A (200 mg) obtained in Example 1 was dissolved in butyl acetate (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (102 mg, yield 51%) of compound A as a white solid. Example 2-3-3
The compound A (200 mg) obtained in Example 1 was dissolved in methyl isobutyl ketone (2 ml) with heating under reflux. Heptane (2 ml) was added dropwise and the mixture was stirred for 6 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (168 mg, yield 84%) of compound A as a white solid. Example 2-3-4
The compound A (200 mg) obtained in Example 1 was dissolved in ethanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (56 mg, yield 28%) of compound A as a white solid. Example 2-3-5
The compound A (200 mg) obtained in Example 1 was dissolved in ethyl acetate (2 ml) with heating under reflux. Heptane (1.6 ml) was added dropwise and the mixture was stirred for 6 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (166 mg, yield 83%) of compound A as a white solid. Example 2-3-6 The compound A (200 mg) obtained in Example 1 was dissolved in methyl ethyl ketone (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 6 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (123 mg, yield 62%) of compound A as a white solid. Example 2-3-7
The compound A (200 mg) obtained in Example 1 was dissolved in 1-propanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (91 mg, yield 46%) of compound A as a white solid. Example 2-3-8 The compound A (200 mg) obtained in Example 1 was dissolved in isopropanol (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (88 mg, yield 44%) of compound A as a white solid. Example 2-3-9
The compound A (200 mg) obtained in Example 1 was dissolved in cumene (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (188 mg, yield 94%) of compound A as a white solid. Example 2-3-10
The compound A (200 mg) obtained in Example 1 was dissolved in anisole (2 ml) with heating under reflux. The mixture was stirred for 17 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (107 mg, yield 54%) of compound A as a white solid. Example 2-3-11
The compound A (200 mg) obtained in Example 1 was dissolved in acetone (2 ml) with heating under reflux. Heptane (2 ml) was added dropwise and the mixture was stirred for 16.5 hr while allowing to cool. Heptane (4 ml) was further added, and the mixture was further stirred for 24 hr. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (134 mg, yield 67%) of compound A as a white solid. Example 2-3-12
The compound A (200 mg) obtained in Example 1 was dissolved in ethanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (129 mg, yield 65%) of compound A as a white solid. Example 2-3-13
The compound A (200 mg) obtained in Example 1 was dissolved in isopropanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (166 mg, yield 83%) of compound A as a white solid. Example 2-3-14 The compound A (200 mg) obtained in Example 1 was dissolved in 1-propanol (2 ml) with heating under reflux. Heptane (4 ml) was added dropwise and the mixture was stirred for 19 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (158 mg, yield 79%) of compound A as a white solid. Example 2-3-15
The compound A (200 mg) obtained in Example 1 was dissolved in isobutanol (2 ml) with heating under reflux. The mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (131 mg, yield 66%) of compound A as a white solid. Example 2-3-16 The compound A (200 mg) obtained in Example 1 was dissolved in toluene (2 ml) with heating at 100°C. The mixture was stirred for 37 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (190 mg, yield 95%) of compound A as a white solid.
Example 2-3-17
The compound A (200 mg) obtained in Example 1 was dissolved in methyl butyl ketone (2 ml) with heating at 60°C. Heptane (1.8 ml) was added dropwise and the mixture was stirred for 37 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (191 mg, yield 96%) of compound A as a white solid. Example 2-3-18
The compound A (200 mg) obtained in Example 1 was dissolved in chloroform (1 ml) with heating at 60°C. Isopropyl ether (1.8 ml) was added dropwise and the mixture was stirred for 37 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (184 mg, yield 92%) of compound A as a white solid. Example 2-3-19
The compound A (200 mg) obtained in Example 1 was dissolved in tetrahydrofuran (1 ml) by heating at 60°C. Isopropyl ether (2 ml) was added dropwise and the mixture was stirred for 41 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (144 mg, yield 72%) of compound A as a white solid. Example 2-3-20
The compound A (200 mg) obtained in Example 1 was dissolved in isobutanol (2 ml) with heating under reflux.
Heptane (2 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (160 mg, yield 80%) of compound A as a white solid.
Example 2-3-21
The compound A (200 mg) obtained in Example 1 was dissolved in butanol (2 ml) with heating under reflux. Heptane (2 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (152 mg, yield 76%) of compound A as a white solid.
Example 2-3-22
The compound A (200 mg) obtained in Example 1 was dissolved in isobutyl acetate (2 ml) with heating under reflux.
The mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (140 mg, yield 70%) of compound A as a white solid. Example 2-3-23
The compound A (200 mg) obtained in Example 1 was dissolved in isobutyl acetate (2 ml) with heating under reflux.
Heptane (2 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II
(178 mg, yield 89%) of compound A as a white solid.
Example 2-3-24
The compound A (200 mg) obtained in Example 1 was dissolved in butyl acetate (2 ml) with heating under reflux. Heptane (1.5 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II
(158 mg,. yield 78%) of compound A as a white solid.
Example 2-3-25 The compound A (200 mg) obtained in Example 1 was dissolved in anisole (2 ml) by heating at 110°C. Heptane (2 ml) was added dropwise and the mixture was stirred for 21 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (187 mg, yield 89%) of compound A as a white solid. Example 2-3-26
The compound A (200 mg) obtained in Example 1 was dissolved in butyl acetate (2 ml) with heating under reflux. After rapid cooling, the mixture was stirred for 2 hr. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (131 mg, yield 66%) of compound A as a white solid. Example 2-4: Production of crystal form II of the compound A Step 1
1- ( (S) -l-tert-butyldimethylsilyloxymethyl-2-methylpropyl) - 6- (3-chloro-2-fluorobenzyl) -7-fluoro-4-oxo-l ,4-dihydroquinoline- 3-carboxylic acid ethyl ester (48 g, 86 mmol) obtained in Example 1, Step 5 was dissolved in methanol (300 ml) , water (5 ml) and 28% sodium methoxide methanol solution (176 ml, 862 mmol) were added, and the mixture was heated under reflux for 24 hr. The reaction mixture was allowed to cool to room temperature, neutralized with 6N hydrochloric acid and methanol was evaporated under reduced pressure. Water was added to the obtained solution and, after stirring, the precipitated solid was collected by filtration. The obtained solid was dissolved in ethyl acetate, washed with water, and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The obtained residue was recrystallized from ethyl acetate-hexane to give compound A
(primary crystal 29.5 g, secondary crystal 2.8 g, in total 32.3 g, yield 86%) as a white solid, m.p. 151-152°C XH NMR (DMSO-d6300MHz) (δ) ppm: 0.72 (3H, d, J=6.5Hz), 1.16 (3H, d, J=6.5Hz), 2.30-2.50 (IH, m) , 3.70-3.90 (IH, m) , 3.90-4.00 (IH, m) , 4.03 (3H, s) , 4.12 (2H,s), 4.80-4.90 (IH, m) , 5.19 (IH, t) , 7.19-7.25 (2H, m) , 7.46-7.51 (2H, m) , 8.04 (IH, s) , 8.88 (IH, s) , 15.44 (IH, s) MS (ESI) : M+ 448 Step 2
Compound A (32.3 g) obtained in Step 1 was dissolved in butyl acetate (160 ml) with heating under reflux. The crystal form II of Example 2 was seeded at 63°C and the mixture was stirred for 3 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give the crystal of compound A (crystal form II) (24.79 g, yield 77%) as a white solid.
Example 2-5: Production of crystal form II of the compound A Step 1
CI
Figure imgf000042_0001
1- ( (S) -l-tert-butyldimethylsilyloxymethyl-2-methylpropyl) - 6- (3-chloro-2-fluorobenzyl) -7-fluoro-4-oxo-l , 4-dihydroquinoline- 3-carboxylic acid ethyl ester (19 g, 33 mmol) obtained in Example 1, Step 5 was dissolved in isopropanol (100 ml) , IN aqueous sodium hydroxide solution (200 ml, 200 mmol) was added, and the mixture was heated under reflux for 2.5 hr. The reaction mixture was allowed to cool to room temperature, and the mixture was filtered through Celite. The filtrate was acidified by adding concentrated hydrochloric acid, and stirred at room temperature for 2 hr. The precipitated solid was collected by filtration and vacuum dried to give 6- (3-chloro-2- fluorobenzyl) -7-fluoro-1- ( (S) -l-hydroxymethyl-2-methylpropyl) -4- oxo-1 ,4-dihydroquinoline-3-carboxylic acid (12 g, yield 82%) as a pale-yellow solid. XH NMR(DMSO-d6 400MHz) (δ) ppm: 0.71(3H, d, J=6.5Hz) , 1.13(3H, d, J=6.5Hz) , 2.36 (IH, br) , 3.77 (IH, br) , 3.94 (IH, br) , 4.25 (2H, s) , 4.77(1H, br) , 5.16(1H, t, J=2.4Hz) , 7.19-7.23 (IH, m) , 7.32- 7.35(1H, m) , 7.48-7.52 (IH, m) , 8.24-8.28 (2H, m) , 9.00(1H, s) , : 15.00(1H, s)
Step 2
Figure imgf000043_0001
The compound (12 g, 27 mmol) obtained in Step 1 was 0 dissolved in methanol (64 ml) , 28% sodium methoxide methanol solution (52 ml, 256 mmol) was added, and the mixture was heated under reflux for 24 hr. The reaction mixture was allowed to cool to room temperature and filtered through Celite. The filtrate was concentrated under reduced pressure. The residue5 was acidified by adding water (360 ml) and concentrated hydrochloric acid, and extracted with ethyl acetate. The organic layer was washed successively with' water and saturated brine and dried over sodium sulfate. The mixture was ' filtered, and the filtrate was concentrated under reduced pressure to give° a crude product (13 g) as a brown oil. The obtained crude product (13 g) was dissolved in isobutyl acetate (60 ml) by heating and, after seeding, the mixture was stirred for 23 hr while allowing to cool. The precipitated solid was collected by filtration, and vacuum dried to give compound A (9.2 g, yield5 75%) as a white solid. H NMR (DMSO-d6300MHz) (δ) ppm: 0.72 (3H, d, J=6.5Hz), 1.16 (3H, d, J=6.5Hz), 2.30-2.50 (IH, m) , 3.70-3.90 (IH, m) , 3.90-4.00 (IH, m) , 4.03 (3H, s) , 4.12 (2H,s) , 4.80-4.90 (IH, m) , 5.19 (IH, t) , 7.19-7.25 (2H, m) , 7.46-7.51 (2H, m) , 8.04(1H, s) , 8.88 (IH, s) ,0 15.44 (IH, s)
MS (ESI) : M+ 448 Step 3
Figure imgf000044_0001
2- (2 ,4-Difluoro-5-iodobenzoyl) -3-dimethylaminoacrylic acid ethyl ester (20 g) obtained in Example 1, Step 2 was subject to slurry washing with a mixed solvent of ethyl acetate (60 ml) and hexane (40 ml) and heated under reflux. The mixture was filtered, and the remaining solid was vacuum dried to give 7- fluoro-1- ( (S) -l-hydroxymethyl-2-methylpropyl) -6-iodo-4-oxo-l ,4- dihydroquinoline-3-carboxylic acid ethyl ester (18 g, yield 94%) as a beige solid.
XR NMR(DMSO-d6 300MHz) (δ) ppm: 0.72 (3H, d, J=6.6Hz), 1.10 (3H, d, J=6.6Hz), 1.28 (3H, t, J=7.0Hz), 2.27 (IH, br) , 3.77 (IH, br) , 3.86 (IH, br) , 4.23 (2H, q, J=7.0Hz), 4.56(1H, br) , 5.12 (IH, t, J=4.9Hz), 8.09 (IH, d, J=ll.lHz), 8.62 (IH, d, J=7.5Hz), 8.68 (IH, s)
MS (ESI) : M+ 448 Step 4
Figure imgf000044_0002
The compound (19 g, 42 mmol) obtained in Step 3 was dissolved in dimethylformamide (65 ml), imidazole (3.4 g, 49.9 mmol) and tert-butyldimethylsilyl chloride (7.2 g, 47.8 mmol) were added, and the mixture was stirred at room temperature for 1.5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water, saturated aqueous ammonium chloride solution and saturated brine, and dried over sodium sulfate.- The organic layer was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (24 g) of 1- ( (S) -l-tert-butyldimethylsilyloxymethyl-2-methylpropyl) - 7-fluoro-6-iodo-4-oxo-l ,4-dihydroquinoline-3-carboxylic acid ethyl ester as a beige amorphous form.
XH NMR(CDC13 400MHz) (δ) ppm: -0.07 (3H, s) , -0.05(3H, s) , 0.77(9H, 5 s) , 0.84(3H,d, J=6.5Hz), 1.18(3H, d, J=6.5Hz), 1.40(3H, t,
J=7.2Hz) , 2.35-2.50UH, m) , 3.85-3.95 (IH, m) , 3.98-4.10 (2H, ) , 4.30-4.40(2H, m) , 7.26(lH,s) , 8.64(1H, s) , 8.94(1H, d, J=7.2Hz) MS (ESI) : M+ 562 Step 5
;x r*Et
Figure imgf000045_0001
"ici
' OTBDMS I 0TBDMS
The crude product (24 g) obtained in Step 4 was dissolved in tetrahydrofuran (200 ml) and, under an argon stream, dibenzylidenacetonepalladium(II) (984 mg, 1.7 mmol) and trifurylphosphine (795 mg, 3.4 mmol) were added, and a solution
15 (56 ml, 56 mmol) of IM 3-chloro-2-fluorobenzylzinc bromide obtained in the same manner as in Example 1, Step 5 in tetrahydrofuran was added dropwise at 60°C. After the completion of the dropwise addition, the mixture was stirred with heating at the same temperature for 2 hr. The reaction mixture was 0 allowed to cool to room temperature, saturated aqueous ammonium chloride solution was added, and filtered through Celite, and the filtrate was extracted twice with ethyl acetate. The organic layer was washed successively with water (twice) and saturated brine, and dried over magnesium sulfate. The organic 5 layer was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (30 g) of 1-((S)-1- tert-butyldimethylsilyloxymethyl-2-methylpropyl)-6-(3-chloro-2- fluorobenzyl) -7-fluoro-4-oxo-l ,4-dihydroquinoline-3-carboxylic acid ethyl ester as a brown paste. 0 Step 6
Figure imgf000046_0001
The crude product (30 g) obtained in Step 5 was dissolved in isopropanol (150 ml) , IN aqueous sodium hydroxide solution (300 ml, 300 mmol) was added, and the mixture was heated under reflux for 2.5 hr. The reaction mixture was allowed to cool to room temperature, and the mixture was filtered through Celite. The filtrate was acidified by adding concentrated hydrochloric acid, and the mixture was stirred at room temperature for 2. hr. The precipitated solid was collected by filtration and vacuum dried to give a crude product (18 g) as a beige solid. The obtained crude product (18 g) was suspended in butyl acetate (90 ml) , and subjected to slurry stirring with heating under reflux for 1 hr. The suspension was allowed to cool to room temperature, filtered and vacuum dried to give 6- (3-chloro-2- fluorobenzyl) -7-fluoro-1- ( (S) -l-hydroxymethyl-2-methylpropyl) -4- oxo-l,4-dihydroquinoline-3-carboxylic acid (11 g, yield 62% (relative to Step 3) ) as a white solid. λR NMR(DMS0-d6 400MHz) (δ) ppm: 0.71 (3H, d, J=6.5Hz), 1.13 (3H, d, J=6.5Hz), 2.36 (IH, br) , 3.77 (IH, br) , 3.94 (IH, br) , 4.25 (2H, s) , 4.77 (IH, br) , 5.16 (lH,t, J=2.4Hz), 7.19-7.23 (IH, m) , 7.32-7.35 (IH, m) , 7.48-7.52 (IH, m) , 8.24-8.28 (2H, m) , 9.00 (IH, s) , 15.00 (IH, s) MS (ESI) : M+ 436 Step 7
' poyS OH ' " 0H
The compound (11 g, 26 mmol) obtained in Step 6 was dissolved in methanol (60 ml) , 28% sodium methoxide methanol solution (52 ml, 256 mmol) was added, and the mixture was heated under reflux for 24 hr. The reaction mixture was allowed to cool to room temperature and filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was acidified by adding water (330 ml) and concentrated hydrochloric acid, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, and dried over sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (12 g) as a brown oil. The obtained crude product (12 g) was dissolved in isobutyl acetate (60 ml) by heating under reflux. A seed crystal (crystal form II of compound A) was seeded, and the mixture was stirred for 23 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give compound A (8.2 g, yield 71%) as a white solid.
XR NMR (DMSO-de 300MHz) (δ) Ppm: 0.72 (3H, d, J=6.5Hz), 1.16 (3H, d, J=6.5Hz), 2.30-2.50 (IH, m) , 3.70-3.90 (IH, m) , 3.90-4.00 (IH, m) , 4.03 (3H, s) , 4.12 (2H,s), 4.80-4.90 (IH, m) , 5.19 (IH, t) , 7.19-7.25 (2H, m) , 7.46-7.51 (2H, m) , 8.04(1H, s) , 8.88 (IH, s) , 15.44 (IH, s) MS (ESI) : M+ 448 Step 8
Compound A (7.66 g) obtained in Step 7 and compound A (9.17 g) obtained in Step 2 were dissolved in isobutyl acetate (84 ml) by heating under reflux and the mixture was stirred for 16 hr while allowing to cool. The precipitated solid was collected by filtration and vacuum dried to give crystal form II (14.73 g, yield 88%) of compound A as a white solid. Example 2-6: Production of crystal form II of the compound A Step 1
Figure imgf000047_0001
2,4-Difluorobenzoic acid (100 g, 633 mmol) was dissolved in trifluoromethanesulfonic acid (400 ml) and N-iodosuccinimide (157 g, 696 mmol) was added by portions at not more than 5°C. After the completion of the addition, the mixture was stirred at 50°C for 1.5 hr. The reaction mixture was poured into iced water, and the mixture was stirred for 1 hr. The precipitated solid was collected by filtration, washed successively with water and hexane , and vacuum dried to give 2 , 4-difluoro-5-iodobenzoic acid (179 g yield quantitative) as a white solid. XH NMR(CDC13 300MHz) (σ) ppm: 6.94(1H, dd, J=10.3, 10.3Hz), 8.46 (IH, d, J=7.5Hz) Step 2
Figure imgf000048_0001
The compound (28 g, 100 mmol) obtained in Step 1 was dissolved in ethyl acetate (300 ml) , oxalyl chloride (11 ml, 122 mmol) and dimethylformamide (catalytic amount) were added, and the mixture was stirred at room temperature for 2 hr. The filtrate was concentrated under reduced pressure and azeotroped with toluene. The residue was dissolved in tetrahydrofuran (100 ml) , this solution was added dropwise to a solution of ethyl
3,3-dimethylaminoacrylate (17 g, 120 mmol) • and triethylamine (21 ml, 150 mmol) in tetrahydrofuran (100 ml) , and the mixture was heated under reflux for 3 hr. The reaction mixture was allowed to cool and ethyl acetate (200 ml) was added. The mixture was washed successively with water (twice) and saturated brine, and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The obtained residue was subject to slurry stirring with a mixed solvent of diethyl ether (50 ml) and hexane (50 ml) . The mixture was filtered- and the remaining solid was vacuum dried to give a crude product (26 g, yield 63%) of 2- (2,4-difluoro-5- iodobenzoyl) -3-dimethylaminoacrylic acid ethyl ester as a yellow solid.
Step 3
Figure imgf000049_0001
The crude product (22 g, 55 mmol) obtained in Step 2 was dissolved in tetrahydrofuran (110 ml), (S) - (+) -valinol (6.8 ,g, 65.8 mmol) was added, and the mixture was stirred with heating at 50°C for 30 min. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (100 ml) , washed successively with water and saturated brine, and dried over magnesium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in dimethylformamide (80 ml) , potassium carbonate (19 g, 137 mmol) was added, and the mixture was stirred with heating at 60°C for 1.5 hr. The reaction mixture was allowed to cool to room temperature and concentrated under reduced pressure. Water (250 ml) was added to the obtained residue and the mixture was stirred at room temperature for 30 min. The precipitated solid was collected by filtration. The obtained solid was washed successively with a mixed solvent of water (100 ml) , ethyl acetate (10 ml) and hexane (40 ml) and vacuum dried to give 7-fluoro-1- ( (S) -l-hydroxymethyl-2- methylpropyl) -6-iodo-4-oxo-l , 4-dihydroquinoline-3-carboxylic acid ethyl ester (22 g, yield 88%) as a pale-yellow solid. XR NMR(DMSO-d6 300MHz) (δ) ppm: 0.72 (3H, d, J=6.6Hz), 1.10 (3H, d, J=6.6Hz), 1.28 (3H, t, J=7.0Hz), 2.27 (IH, br) , 3.77 (IH, br) 3.86 (IH, br) , 4.23 (2H, q, J=7.0Hz), 4.56(1H, br) , 5.12 (IH, t, J=4.9Hz) , 8.09 (IH, d, J=ll.lHz), 8.62 (IH, d, J=7.5Hz), 8.68 (IH, s) • MS (ESI) : M+ 448 Step 4
Figure imgf000050_0001
The compound (22 g, 48 mmol) obtained in Step 3 was dissolved in dimethylformamide (60 ml), imidazole (3.9 g, 57.7 mmol) and tert-butyldimethylsilyl chloride (8.0 g, 53.0 mmol) were added, and the mixture was stirred at room temperature for 1.5 hr. The reaction mixture was concentrated under reduced pressure, and the obtained residue was dissolved in ethyl acetate (200 ml) , washed successively with water (twice) and saturated brine, and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate : hexane=3 : 7 to 4:6) to give 1-((S)- l-tert-butyldimethylsilyloxymethyl-2-methylpropyl) -7-fluoro-6- iodo-4-oxo-l,4-dihydroquinoline-3-carboxylic acid ethyl ester (25 g, yield 92%) as a white wax. H NMR(CDC13 400MHz) (δ) ppm: -0.07(3H, s) , -0.05(3H, s) , 0.77(9H, s) , 0.84(3H,d, J=6.5Hz), 1.18(3H, d, J=6.5Hz), 1.40(3H, t, J=7.2Hz), 2.35-2.50 (IH, m) , 3.85-3.95 (IH, m) , 3.98-4.10 (2H, m) , 4.30-4.40(2H, m) , 7.26(lH,s), 8.64(1H, s) , 8.94(1H, d, J=7.2Hz) MS (ESI) : M+ 562 Step 5
Figure imgf000050_0002
The compound (25 g, 44 mmol) obtained in Step 4 was dissolved in tetrahydrofuran (200 ml) and, under an argon stream, dibenzylidenacetonepalladium(II) (1.0 g, 1.8 mmol) and trifurylphosphine (824 mg, 3.5 mmol) were added. A solution (58 ml, 58 mmol) of IM 3-chloro-2-fluorobenzylzinc bromide obtained in the same manner as in Example 1, Step 5 in tetrahydrofuran was added dropwise at 60°C. After the completion of the dropwise addition, the mixture was heated under reflux for 3 hr. The reaction mixture was allowed to cool to room temperature, ethyl acetate (200 ml) was added, washed successively with IN hydrochloric acid, water, saturated aqueous sodium hydrogen carbonate, water and saturated brine, and dried over sodium sulfate. The mixture was filtered and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate: hexane=4 : 6 to 1:1) to give 1- ( (S) -l-tert-butyldimethylsilyloxymethyl-2- methylpropyl) -6- (3-chloro-2-fluorobenzyl) -7-fluoro-4-oxo-l , 4- dihydroquinoline-3-carboxylic acid ethyl ester (17 g, yield 68%) as a pale-yellow oil. lE NMR(CDC13 400MHz) (δ) ppm: -0.09 (3H, s) , -0.05(3H, s) , 0.75(9H, s) , 0.85(3H,d, J=6.7Hz), 1.18(3H, d, 6.7Hz), 1.39(3H, t, J=7.1Hz), 2.45(1H, br) , 3.89-3.92 (IH, m) , 3.98-4.02 (IH, m) , 4.07-4.12 (IH, m) , 4.12(2H, s) , 4.34-4.41 (2H, m) , 6.96-7.00 (IH, m) , 7.03-7.05(lH, m) , 7.21-7.24 (IH, m) , 7.26-7.29 (IH, m) , 8.39(1H, d, J=8.8Hz), 8.63(1H, s) Step 6
Figure imgf000051_0001
The compound (17 g, 30 mmol) obtained in Step 5 was dissolved in methanol (120 ml) , 28% sodium methoxide methanol solution- (62 ml, 304 mmol) was added, and the mixture was heated under reflux for 19 hr. The reaction mixture was allowed to cool to room temperature, water (200 ml) was added, and methanol was evaporated under reduced pressure. The residue was acidified by adding concentrated hydrochloric acid, extracted with ethyl acetate, and dried over sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a crude product (14 g) of compound A as a pale- yellow oil. Step 7
Compound A (14.11 g) obtained in Step 6 was suspended in a mixed solvent of ethyl acetate (20 ml) and hexane (20 ml) at room temperature, a seed crystal (crystal form II of compound A) was seeded, and the mixture was stirred for 1 hr. The suspension was filtered, and the remaining solid was vacuum dried to give compound A (crystal form II, 10.40 g, yield 77%) as a white solid.
Example 3: Production of crystal form III of the compound A Example 3-1: Production of crystal form III of the compound A
The crystal form II of compound A (10.0 g, 22.3 mmol) obtained in Example 2-2 was added to isobutyl acetate (30 mL) and the crystal was dissolved by heating under reflux. The solution was cooled to 90°C, and stirred for 5 hr to allow precipitation of crystals. This solution was further allowed to cool to room temperature, and further stirred for 12 hr. The precipitated crystal was collected by filtration. The obtained crystal was washed with isobutyl acetate (10 mL) and vacuum dried to give a white crystal (9.85 g, yield 98.5%) . Since this crystal was confirmed to be different from crystal form II by XRPD analysis, a crystal showing the XRPD chart (Fig. 1) as this crystal was taken as crystal form III. Example 3-2: Production of crystal form III of the compound A The crystal form II of compound A (250 g, 558 mmol) obtained in Example 2-2 was added to isobutyl acetate (750 mL) . A seed crystal (12.5 g) of the crystal form III of compound A obtained in Example 3 was added at room temperature and the mixture was stirred for 17 hr. The precipitated crystal was collected by filtration. The obtained crystal was washed with isobutyl acetate (250 mL) , and vacuum dried to give the object product (crystal form III, 259 g, yield 98.6%) as a white crystal. This crystal was confirmed to be equivalent to the standard product of the crystal (crystal form III of compound A obtained in Example 3-1) by XRPD analysis.
Example 3-3: Production of crystal form III of the compound A Compound A (crystal form II, 10.0 g, 22.3 mmol) obtained in Example 2-2 was added to isopropanol (30 mL) , and the mixture was heated under reflux to dissolve the crystal. The solution was cooled to 70°C, a seed crystal (10 mg) of the crystal form III of compound A obtained in Example 3-1 was added, and the mixture was stirred .for 5 hr. This mixture was further allowed to cool to room temperature, stirred for 12 hr, and the crystal was collected by filtration. The obtained crystal was washed with isopropanol (10 mL) , and vacuum dried to give the object product (crystal form III, 9.72 g, yield 97.2%) as a white crystal. This crystal was confirmed to be equivalent to the standard product of the crystal (crystal form III of compound A obtained in Example 3-1) by XRPD analysis. Example 3-4: Production of crystal form III of compound A
The crystal form II of compound A (7.00 g, 15.6 mmol) obtained in Example 2-2 was added to a mixed solution of ethanol (52.5 mL) and water (7 mL) and dissolved by heating. Water (28 mL) was added, a seed crystal (10 mg) of the object product was added at 70°C and the mixture was stirred for 4 hrs. After allowing to cool to room temperature, the mixture was ice-cooled and further stirred for 2 hrs , and the crystals were collected by filtration. The obtained crystals were washed with a mixed solution of cool ethanol (8.4 mL) and water (5.6 mL) and vacuum dried to give the object product as white crystals (crystal form III, 6.77 g, yield 96.8%). This crystal was confirmed to be equivalent to the standard product (Example 3-1) by XRPD analysis.
Experimental Example The property values of each crystal form were determined by the following analysis tests , and the stability test of each crystal form was performed using them as indices. Sample
Unless otherwise specified, the aforementioned crystal (crystal form I) obtained in Reference Example 1, the crystal (crystal form II) obtained in Example 1 and the crystal (crystal form III) obtained in Example 3-1 were used as samples. Analysis test 1. X-ray powder diffractometry This test aims at obtaining X-ray powder diffraction patterns to specify the crystal form of the crystals obtained in Reference Example 1 , Example 1 and Example 3-1. The diffraction patterns are utilized to specify the crystal form, evaluate the stability, to determine the purity and the like. A sample was fixed to an aluminum cell, and the measurement was performed using an X-ray powder diffractometer (RINT 2000/PC Ultima"1", manufactured by Rigaku Corporation, X-ray source: Cu-K(χl ray, tube voltage: 40 kV, tube electric current: 40 mA, scan speed: 5° per min, step width: 0.02°, diffraction angle: 5-40°) , based on which the diffraction patterns were obtained. The obtained diffraction patterns are shown in Fig. 1.
As shown in Fig. 1, X-ray powder diffraction patterns obtained from respective samples were different.
Therefore it was confirmed that the crystals obtained in Reference Example 1 , Example 1 and Example 3-1 were distinct from each other, and show characteristic diffraction patterns as shown in the X-ray powder diffraction pattern. Therefore, in the present specification, they were named as crystal form I, crystal form II and crystal form III, based on these X-ray powder diffraction patterns.
For specification of the crystal form, the diffraction peak characteristic of each crystal may be evaluated in a comprehensive manner based on the diffraction chart in Fig. 1. The main diffraction peaks and characteristic diffraction peaks specified from the diffraction patterns in Fig. 1 are shown below. [Crystal form I]
Main diffraction peak:2θ=6.58, 14.40, 14.64, 15.24, 16.48, 19.16, 20.90, 21.14, 22.24, 24.74, 25.64, 26.12, 27.20°;
Characteristic diffraction peak:2θ=6.58, 14.40, 19.16, 20.90,
21.14°.
[Crystal form II]
Main diffraction peak: 20=6.56, 9.04, 13.20, 14.62, 15.24, 16.48, 19.86, 20.84, 21.22, 22.24, 25.22, 25.96, 26.12, 27.34°;
Characteristic diffraction peak:2θ=6.56, 13.20, 19.86, 20.84,
21.22, 25.22°.
[Crystal form III]
Main diffraction peak:2θ=8.54, 14.02, 15.68, 15.90, 16.00, 17.06, 17.24, 17.84, 18.12, 19.50, 19.90, 22.26, 22.68, 23.02, 24.16,
24.76, 25.18, 25.74, 25.98, 27.50, 28.80, 30.38, 30.72, 32.54°;
Characteristic diffraction peak:2θ=8.54, 14.02, 15.68, 17.06,
17.24, 24.16, 25.74°.
2. Thermal analysis This test aims at the measurement of the enthalpy and extrapolated onset temperature at an endothermic peak on the
Differential Scanning Calorimetry (DSC) measurement curve.
These values are among the indices of the stability of the above-mentioned crystal form I, crystal form II and crystal form III, and can be used as an index to specify the crystal form.
2.1. Enthalpy and extrapolated onset temperature of crystal form
I and crystal form II
Crystal form I and crystal form II were subjected to measurement using a Differential Scanning Calorimetry (DSC) measurement apparatus (DSC8240, manufactured by Rigaku Corporation) , under atmosphere, measurement sample 5+1 mg, temperature rise rate: 10°C/min, aluminum open pan, and alumina oxide as a reference. The enthalpy and extrapolated onset temperature at an endothermic peak on the obtained DSC curve were determined.
2.2. Enthalpy and extrapolated onset temperature of crystal form III
Crystal form III was subjected to measurement using a DSC measurement apparatus (DSC8240, manufactured by Rigaku
Corporation), under atmosphere, measurement sample 5.0+0.5 mg, temperature rise rate: 5°C/min, aluminum closed pan, and alumina oxide as a reference. The enthalpy and extrapolated onset temperature at an endothermic peak on the obtained DSC curve were determined.
The results are shown in Table 1.
Table 1 DSC curve at endothermic peak on enthalpy and extrapolated onset temperature
Figure imgf000056_0001
As shown in Table 1, crystal form III shows greatest enthalpy and highest extrapolated onset temperature among three crystal forms. Thus, crystal form III was confirmed to be most stable form. 3. Purity test This test aims at measurement of the purity of compound A. The purity can be used as indices of chemical stability. 3.1. Purity of compound of crystal form I and crystal form II
Each sample (crystal form I and crystal form II, ca. 10 5 mg) was dissolved in acetonitrile to make an amount of 10 mL and used as a sample solution. This solution (10 μL) was applied to high performance liquid chromatography (HPLC) under the following conditions. The peak area of each sample solution was measured by automatic integration, and the purity was determined0 by the following formula. The purity is shown in the Tables 5 and 6 below.
Purity (%) = 100 - (Asum/As) X 100 5 As: total peak area of peaks obtained from sample solution
Asum: total peak area of peaks other than the main peak obtained from sample solution
Test conditions ° Detector: UV absorptiometer (wavelength: 259 nm)
Column: CAPCELL PAK MG (inner diameter 4.6 cm, length 15 cm, particle size 5 μm, manufactured by Shiseido Co. , Ltd. Column temperature: constant temperature around 40°C
Mobile phase A trifluoroacetic acid solution (1:1000) 5 Mobile phase B solution of trifluoroacetic acid in acetonitrile (1 1000)
Gradient program: As shown in the following Table 2, the mixing ratio of mobile phase A and mobile phase B is changed to control concentration gradient. 0 Table 2
Figure imgf000058_0001
Flow rate: 1 mL/min
3.2. Purity of compound of crystal form III A sample (crystal form III, ca. 50 mg) was dissolved in a mixture (4:1) of mobile phase B and mobile phase A to make an amount of 50 mL, which was used as a sample solution. This solution (1 mL) was precisely measured and a mixture (4:1) of mobile phase B and mobile phase A was added to precisely make an amount of 100 mL, which was used as a standard solution. The sample solution and standard solution (15 μL) was applied to high performance liquid chromatography (HPLC) under the following conditions . The peak area of each solution' was measured by automatic integration, and the purity was determined by the following formula. The purity is shown in the Table 7 below.
Purity (%) = 100 - (Asura/Ar)
Ar: peak area of main peak obtained from standard solution
Asum: total peak area of peaks other than the main peak obtained from sample solution
Test conditions Detector: UV absorptiometer (wavelength: 259 nm)
Column: Waters XTerra MC C18 (inner diameter 4.6 cm, length 5 cm, particles diameter 2.5 μm, manufactured by Waters) Column temperature: constant temperature around 40°C Mobile phase A: phosphoric acid is added to dipotassium hydrogenphosphate solution (1-1149) to adjust pH to 7.0 Mobile phase B: acetonitrile Gradient program: As shown in the following Table 3, the mixing ratio of mobile phase A and mobile phase B is changed to control concentration gradient.
Table 3
Figure imgf000059_0001
Flow rate: 0.9 mL/min
4. Solubility test This test aims at measurement of solubility of the crystal in various test solutions and under various pHs. The solubility is one of the indices of the stability of the above-mentioned crystal form I, crystal form II and crystal form III and can be used also as a reference indices of absorbability of crystal form by living organisms .
Each sample (crystal form I type I, crystal form II and crystal form III, ca. 10 mg) was placed in a 10 mL centrifuge tube together with the following test solution (5 mL) and shaken with a shaker (SR-1M; manufactured by Tietech Co., Ltd.) for 14 hours. After shaking, the mixture was centrifuged (3000 rpm, 20 min) and the supernatant was filtered through 0.2 μm pore size - 13 mm diameter polytetrafluoroethylene disk filter (Millex-LG; manufactured by Millipore Corporation) . The measurement was performed by high performance liquid chromatography (HPLC) . The results are shown in Table 4.
Table 4 Solubility Test
Figure imgf000060_0001
1) Japanese Pharmacopoeia, General Test Method, Disintegration Test Method, 1st fluid. Hydrochloric acid (7.0 mL) and water are added to sodium chloride (2.0 g) to make an amount of 1000 mL. This solution is transparent and colorless and has a pH of about 1.2.
2) Japanese Pharmacopoeia, General Test Method, Disi•ntegrati■on Test Method, 2nd fluid. 0.2 mol/L sodium hydroxide sample (118 mL) and water are added to 0.2 mol/L potassium disodium phosphate sample (250 mL) to make an amount of 1000 mL. This solution is transparent and colorless and has a pH of about 6.8.
3) Mcllvaine buffer obtained by mixing disodium hydrogenphosphate and citric acid at a given ratio to adjust to a given pH.
From the above-mentioned results , it was confirmed that crystal form II has higher solubility than crystal form III. 5. Stability test
A stability test of each sample was performed under the following preservation conditions . The results of crystal form I are shown in Table 5, the results of crystal form II are shown in Table 6, and the results of crystal form III are shown in Table 7. As shown in Table 6 and Table 7, crystal form II and crystal form III did not show any difference in the test results under all preservation conditions , as compared to the initial . sample. In contrast, as shown in Table 5, crystal form I showed changes in the X-ray powder diffraction pattern obtained from sample after preservation under preservation condition #3 (80°C, preservation in an open container for 3 days) and preservation condition #5 (60°C, preservation in an open container for 3. weeks) , and the X-ray powder diffraction pattern of crystal form I was observed to have overlapped with the X-ray powder diffraction pattern derived from crystal form II. Thus, it was evaluated that a part of the sample showed crystal transition to crystal form II during preservation. The X-ray powder diffraction patterns of the samples preservation sample under preservation conditions #1-6 of crystal form I are shown in Fig. 2.
Table 5 Results of stability test of crystal form I
Figure imgf000062_0001
R.H. : relative humidity
XRD: X-ray powder diffractometry Table 6 Results of stability test of crystal form II
Figure imgf000063_0001
R.H. : relative humidity
XRD: X-ray powder diffractometry Table 7 Results of stability test of crystal form III
Figure imgf000064_0001
R.H. : relative humidity
XRD: X-ray powder diffractometry
From the results of the above-mentioned stability test, it was observed that the crystal form I was unstable but crystal form II and crystal form III were extremely stable under various preservation conditions. Therefore, it was evidenced that crystal form II and crystal form III are preferable for use as a pharmaceutical product and the like. As for the absorbability by living organisms, crystal form II is more preferable, and crystal form III is more preferable because it is the most stable crystal.
Since crystal form II and crystal form III are both stable, a mixed crystal of them can be used for the present invention. Experimental Example
The following explains evaluation methods of the HIV integrase inhibitory activity of a crystal or a mixed crystal of compound A of the present invention, (i) Construction of recombinant integrase gene expression system The 185th phenylalanine of HIV integrase full length gene
(J. Virol., 67, 425-437 (1993)) was substituted by histidine and inserted into the restriction enzyme Ndel and Xhol sites of the plasmid pET21a(+) (manufactured by Novagen) , whereby an integrase expression vector pET21a-IN-F185H was constructed. (ii) Production and purification of integrase protein
Escherichia coli recombinant BL21(DE3) transformed with plasmid pET21a-IN-Fl85H obtained in (i) was shake cultured at 30°C in a liquid medium containing ampicillin. When the culture reached the logarithmic growth phase, isopropyl-β-D- thiogalactopyranoside was added to promote expression of integrase gene. The culture was continued for 3 hr to promote accumulation of the integrase protein. The recombinant E. coli was collected in pellets by centrifugal separation and preserved at -80°C. The E. coli was suspended in Lysis buffer (20 mM HEPES (pH 7.5), 5 mM DTT, 10 mM CHAPS, 10% glycerol) containing IM sodium chloride and subjected to repeat pressurization and depressurization for rupture, and centrifugal separation at 4°C, 40,000χg, 60 min to recover a water-soluble fraction (supernatant) . This was diluted 10-fold with Lysis buffer free of sodium chloride, mixed with SP-Sepharose (manufactured by
Pharmacia Corporation) and stirred at 4°C for 60 min to allow adsorption of integrase protein to the resin. The resin was washed with Lysis buffer containing 100 mM sodium chloride and the integrase protein was eluted with Lysis buffer containing IM sodium chloride.
The eluted integrase protein solution was applied to a
Superdex 75 (Pharmacia Corporation) column for gel filtration. The protein was eluted with Lysis buffer containing IM sodium chloride .
The obtained fractions of the integrase protein were collected and preserved at -80°C.
(iii) Preparation of DNA solution The following DNA synthesized by Greiner was dissolved in
TE buffer (10 mM Tris-hydrochloric acid (pH 8.0), 1 mM EDTA) and mixed with donor DNA, target DNA, and each complementary strand
(+ and - strands) to 1 μM. The mixture was heated at 95°C for 5 min, 80°C for 10 min, 70°C for 10 min, 60°C for 10 min, 50°C for 10 min and 40°C for 10 min and preserved at 25°C to give a double stranded DNA, which was used for the test. Donor DNA (- strand having biotin attached to the 5' terminal)
Donor + strand: 5 '-Biotin-ACC CTT TTA GTC AGT GTG GAA AAT CTC
TAG CA-3' (SEQ ID NO:l) Donor - strand: 5 '-ACT GCT AGA GAT TTT CCA CAC TGA CTA AAA G-3 '
(SEQ ID NO: 2)
Target DNA (+, - strands both having digoxigenin added at 3' terminal)
Target + strand: 5'-TGA CCA AGG GCT AAT TCA CT-Dig-3 ' (SEQ ID NO: 3)
Target - strand: 5'-AGT GAA TTA GCC CTT GGT CA-Dig-3 ' (SEQ ID
NO: 4)
(iv) Determination of enzyme (HIV integrase) inhibitory activity The donor DNA was diluted with TE buffer to 10 nM, of which 50 μl was added to each well of streptavidin-coated microtiter plate (manufactured by Roche) and allowed to adsorb at 37°C for 60 min. The DNA was then washed with phosphate buffer (Dulbecco PBS, Sanko Junyaku Co., Ltd.) containing 0.1% Tween 20 and phosphate buffer. Then, a reaction mixture (70 μl, see the following * for the composition) , a test substance (10 μl) diluted with the reaction mixture and 100 μg/ml integrase protein (10 μl) were added to each well and reacted at 37°C for 60 min.
Then, 50 nM target DNA (10 μl) was added, reacted at 37°C for 10 min and washed with phosphate buffer containing 0.1% Tween 20 to stop the reaction.
Then, 100 mU/ml peroxidase labeled anti-digoxigenin antibody solution (manufactured by Roche, 100 μl) was added, and the mixture was reacted at 37°C for 60 min, followed by washing with phosphate buffer containing 0.1% Tween 20.
A peroxidase color solution (manufactured by Bio Rad, 100 μl) was added and allowed to react at room temperature for 4 min. The color reaction was stopped by adding IN sulfuric acid (100 μl) . The absorbance at 450 nm was measured.
The HIV integrase inhibitory activity (IC50) of the compound A of the present invention was calculated from the inhibition rate according to the following formula. The results are shown in Table 8.
Inhibition rate (%) =[1- (Object-Blank) / (Control-Blank) ] X 100
Object; absorbance of well in the presence of test compound Control; absorbance of well in the absence of test compound Blank; absorbance of well in the absence of test compound, in the absence of integrase protein
Composition of the reaction mixture: 30 mM morpholinopropanesulfonic acid (MOPS) , 5 mM MgCl2, 3 mM dithiothreithol (DTT) , 0.1 mg/mL bovine serum albumin (BSA) , 5% glycerol, 10% dimethyl sulfoxide (DMSO), 0.01% Tween 20
Table 8
Figure imgf000068_0001
Evaluation of antivirus activity
The effect of combined use of a crystal or a mixed crystal of compound A of the present invention and existent anti-HIV agents can be determined in the following manner.
For example, the effect of combined use of two agents from existent nucleoside reverse transcriptase inhibitors (zidovudine, lamivudine, tenofovir) , non-nucleoside reverse transcriptase inhibitors (efavirenz) or protease inhibitors (indinavir, nelfinavir) and a crystal or a mixed crystal of compound A and the like are evaluated by XTT method using CEM-SS cells infected with HIV-1 IIIB.
In addition, the effect of combined use of three agents of a crystal or a mixed crystal of compound A, zidovudine and lamivudine, or a crystal or a mixed crystal of compound A, tenofovir and lamivudine, and the like is evaluated.
Prior to the combined use test, IC50 and CC50 of each pharmaceutical agent alone are measured. 5 concentrations of pharmaceutical agent a and 9 concentrations of pharmaceutical agent b, determined based on these results, are combined to evaluate the effect of combined use of two agents . For combined use of three agents, a high concentration pharmaceutical agent b and a pharmaceutical agent c are mixed and pharmaceutical agent a and the concentration are combined for evaluation.
The test results of the crystal or mixed crystal of compound A and combination drug alone or in combination thereof are analyzed based on the programs of Prichard and Shipman MacSynergy II version 2.01 and Deltagraph version 1.5d.
A three-dimensional plot is drawn from % inhibition at the concentrations of each combined pharmaceutical agent, obtained from 3 times of tests, with 95% (or 68%, 99%) confidence limits , and the effect of the combined use is evaluated based on the numerical values of μM2% calculated therefrom. The criteria of evaluation are shown in the following.
Definition of interaction μM2% Strong synergistic action >100 Slight synergistic action +51 - +100 Additive action +50 - -50 Slight antagonistic action -51 - -100 Strong antagonistic action <-100
INDUSTRIAL APPLICABILITY
The crystal of compound A of the present invention, which has the above-mentioned particular crystal form, shows an anti- HIV effect as well as superior crystal stability. Therefore, it is useful as a starting material of a pharmaceutical composition, particularly, various pharmaceutical compositions for the prophylaxis and/or treatment of AIDS.
This application is based on patent application No. 2004- 150979 filed in Japan, the contents of which are hereby incorporated by reference. All of the references cited herein, including patents, patent applications and publications, are hereby incorporated in their entireties by reference.

Claims

1. A crystal (crystal form II) of 6- (3-chloro-2-fluorobenzyl) -1- [ (S) -l-hydroxymethyl-2-methylpropyl] -7-methoxy-4-oxo-l ,4- dihydroquinoline-3-carboxylic acid, which has an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 20 (°) of 6.56, 13.20, 19.86, 20.84, 21.22, 25.22° as measured by X-ray powder diffractometer.
2. A crystal (crystal form III) of 6- (3-chloro-2-fluorobenzyl) - 1- [ (S) -l-hydroxymethyl-2-methylpropyl] -7-methoxy-4-oxo-l , 4- dihydroquinoline-3-carboxylic acid, which has an X-ray powder diffraction pattern having characteristic diffraction peaks at diffraction angles 2Θ(°) of 8.54, 14.02, 15.68, 17.06, 17.24, 24.16, 25.74° as measured by X-ray powder diffractometer.
3. A crystal (crystal form III) of 6- (3-chloro-2-fluorobenzyl) - 1- [ (S) -l-hydroxymethyl-2-methylpropyl] -7-methoxy-4-oxo-l , 4- dihydroquinoline-3-carboxylic acid, having an extrapolated onset temperature of 162.1+5.0°C.
4. The crystal of any of claims 1 to 3 , which has a purity of crystal of not less than 70%.
5. A mixed crystal comprising the crystal of claim 1 and the crystal of claim 2 or 3.
6. The mixed crystal of claim 5, wherein the purity of crystal is not less than 70%.
7. A pharmaceutical composition comprising the crystal of any of claims 1 to 4 or the mixed crystal of claim 5 or 6 , and a pharmaceutically acceptable carrier.
8. An integrase inhibitor comprising the crystal of any of claims 1 to 4 or the mixed crystal of claim 5 or 6 as an active ingredient.
9. An antivirus agent comprising the crystal of any of claims 1 to 4 or the mixed crystal of claim 5 or 6 as an active ingredient.
10. An anti-HIV agent comprising the crystal of any of claims 1 to 4 or the mixed crystal of claim 5 or 6 as an active ingredient.
11. An anti-HIV composition comprising the crystal of any of claims 1 to 4 or the mixed crystal of claim 5 or 6 and one or more kinds of other anti-HIV active substances as active ingredients .
12. An anti-HIV agent for a multiple drug therapy with other anti-HIV agent, which comprises the crystal of any of claims 1 to 4 or the mixed crystal of claim 5 or 6 as an active ingredient.
PCT/JP2005/009604 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound WO2005113508A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
MXPA06013405A MXPA06013405A (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound.
EP05726243A EP1636190B1 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound
EP17186674.2A EP3281939B1 (en) 2004-05-20 2005-05-19 Combination comprising a stable crystal of a 4-oxoquinoline compound
NZ551839A NZ551839A (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound
ES05726243T ES2388441T3 (en) 2004-05-20 2005-05-19 Stable crystal of the 4-oxoquinoline compound
DK05726243.8T DK1636190T3 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound
EP23203885.1A EP4299563A3 (en) 2004-05-20 2005-05-19 Combination comprising a stable crystal of a 4-oxoquinoline compound
PL05726243T PL1636190T3 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound
CN2005800161426A CN1956961B (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound
BRPI0510114A BRPI0510114B8 (en) 2004-05-20 2005-05-19 4-oxoquinoline compound crystals, mixed crystals and pharmaceutical composition
AU2005245296A AU2005245296B2 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound
CA2566922A CA2566922C (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound
RS20120306A RS52375B (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compund
SI200531572T SI1636190T1 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound
HK06105469.5A HK1083341A1 (en) 2004-05-20 2006-05-11 Stable crystal of 4-oxoquinoline compound
IL179250A IL179250A0 (en) 2004-05-20 2006-11-14 Stable crystal of 4-oxoquinoline compound and pharmaceutical compositions containing the same
NO20065790A NO339223B1 (en) 2004-05-20 2006-12-14 Stable crystal of 4-oxoquinoline compound
HRP20120681TT HRP20120681T1 (en) 2004-05-20 2012-08-24 Stable crystal of 4-oxoquinoline compound
NO20161297A NO20161297A1 (en) 2004-05-20 2016-08-12 Stable crystal of 4-oxoquinoline compound
NO20190051A NO20190051A1 (en) 2004-05-20 2019-01-15 Stable crystal of 4-oxoquinoline compound
NO20200873A NO20200873A1 (en) 2004-05-20 2020-08-04 Stable crystal of 4-oxoquinoline compound
NO20220690A NO20220690A1 (en) 2004-05-20 2022-06-17 Stable crystal of 4-oxoquinoline compound
NO20230913A NO347902B1 (en) 2004-05-20 2023-08-25 Pharmaceutical composition
FR23C1040C FR23C1040I1 (en) 2004-05-20 2023-11-02 COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-150979 2004-05-20
JP2004150979 2004-05-20

Publications (1)

Publication Number Publication Date
WO2005113508A1 true WO2005113508A1 (en) 2005-12-01

Family

ID=35079161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/009604 WO2005113508A1 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound

Country Status (34)

Country Link
US (6) US7635704B2 (en)
EP (4) EP4299563A3 (en)
JP (1) JP3754064B2 (en)
KR (1) KR20080064909A (en)
CN (1) CN1956961B (en)
AR (2) AR049280A1 (en)
AU (1) AU2005245296B2 (en)
BE (1) BE2024C511I2 (en)
BR (1) BRPI0510114B8 (en)
CA (1) CA2566922C (en)
CY (1) CY1113010T1 (en)
DK (2) DK1636190T3 (en)
ES (2) ES2960824T3 (en)
FI (2) FI3281939T3 (en)
FR (1) FR23C1040I1 (en)
HK (1) HK1083341A1 (en)
HR (2) HRP20231588T3 (en)
HU (2) HUE064615T2 (en)
IL (1) IL179250A0 (en)
LT (1) LT3281939T (en)
LU (1) LUC00334I2 (en)
MX (1) MXPA06013405A (en)
MY (1) MY134672A (en)
NO (6) NO339223B1 (en)
NZ (1) NZ551839A (en)
PE (2) PE20060358A1 (en)
PL (2) PL3281939T3 (en)
PT (2) PT1636190E (en)
RS (2) RS64845B1 (en)
RU (1) RU2330845C1 (en)
SI (2) SI3281939T1 (en)
TW (1) TWI329015B (en)
WO (1) WO2005113508A1 (en)
ZA (1) ZA200610647B (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063869A1 (en) * 2005-11-30 2007-06-07 Japan Tobacco Inc. Process for production of highly pure quinolone compound
WO2007079260A1 (en) 2005-12-30 2007-07-12 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007089030A1 (en) 2006-02-01 2007-08-09 Japan Tobacco Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
WO2007102512A1 (en) 2006-03-06 2007-09-13 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
WO2009006199A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
WO2009036161A1 (en) * 2007-09-11 2009-03-19 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
WO2010091197A2 (en) 2009-02-06 2010-08-12 Gilead Sciences, Inc. Tablets for combination therapy
US7825252B2 (en) 2006-09-12 2010-11-02 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
WO2011004389A3 (en) * 2009-06-18 2011-04-28 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
WO2010137032A3 (en) * 2009-05-14 2011-09-15 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
AU2013203476B2 (en) * 2005-12-30 2016-07-28 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9522912B2 (en) 2014-12-23 2016-12-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9630978B2 (en) 2015-04-02 2017-04-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US9708342B2 (en) 2014-06-20 2017-07-18 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
EP3984536A1 (en) * 2020-10-19 2022-04-20 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
EP3406596A1 (en) * 2002-11-20 2018-11-28 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
KR101636221B1 (en) 2006-07-07 2016-07-04 길리애드 사이언시즈, 인코포레이티드 Modulators of pharmacokinetic properties of therapeutics
LT2487162T (en) * 2007-02-23 2016-11-10 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN102212032B (en) * 2011-04-20 2013-07-31 复旦大学 5-hyroxyquinolone derivatives, and preparation method and application thereof
CN103819402B (en) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 Dust is for drawing Wei intermediate and its preparation method and application
CN103864682B (en) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 A kind of type III angstrom of preparing is for the method drawing Wei Jingti
CN105315203A (en) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 V-type elvitegravir crystal and preparation method thereof
CN106008195B (en) * 2016-05-19 2018-08-03 绍兴文理学院 The preparation method of 2,4- of one kind, bis- fluoro- 5- iodo-benzoic acids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
WO1998045269A1 (en) * 1997-04-08 1998-10-15 Centre National De La Recherche Scientifique (Cnrs) Quinoline derivatives, having in particular antiviral properties, preparation and biological applications thereof
JP3567162B1 (en) 2002-11-20 2004-09-22 日本たばこ産業株式会社 4-oxoquinoline compounds and their use as HIV integrase inhibitors
EP1564210A1 (en) * 2002-11-20 2005-08-17 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567162B1 (en) 1970-09-14 1981-02-16
JPS4826772A (en) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (en) 1989-07-31 1994-07-06 新日本製鐵株式会社 Plasma arc welding method and apparatus
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (en) 1992-05-27 1999-02-22 Ube Industries Aminokinolone derivatives and anti-HIV agents
JP2993316B2 (en) 1992-05-27 1999-12-20 宇部興産株式会社 Aryl or heteroaromatic group-substituted aminoquinolone derivatives and therapeutic agents for AIDS
JPH06199835A (en) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd 8-difluromethoxyquinoline-3-carboxylic acid derivative
JPH06271568A (en) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd 7-phenylpiperazinylquinoline-3-carboxylic acid derivative
CZ12097A3 (en) 1994-07-18 1997-09-17 Ube Industries Trifluoromethylquinolinecarboxylic acid derivatives and pharmaceutical composition containing thereof
JP2930539B2 (en) 1994-07-18 1999-08-03 三共株式会社 Trifluoromethylquinoline carboxylic acid derivative
JPH0826772A (en) 1994-07-22 1996-01-30 Sony Corp Glass for fusing, its production and apparatus for production and production of magnetic head
JP4121151B2 (en) 1996-04-12 2008-07-23 アメリカ合衆国 Compounds derived from acridone useful as anti-neoplastic and antiretroviral agents
JP3776203B2 (en) 1997-05-13 2006-05-17 第一製薬株式会社 ICAM-1 production inhibitor
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PE20011349A1 (en) 2000-06-16 2002-01-19 Upjohn Co 1-ARIL-4-OXO-1,4-DIHYDRO-3-QUINOLINE CARBOXAMIDES AS ANTIVIRAL AGENTS
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
ES2274913T3 (en) 2000-10-12 2007-06-01 MERCK &amp; CO., INC. AZA AND POLIAZA-NAFTALENIL CARBOXAMIDS USEFUL AS INTEGRATED HIV INHIBITORS.
ATE411292T1 (en) 2001-03-01 2008-10-15 Shionogi & Co NITROGEN-CONTAINING HETEROARYL COMPOUNDS WITH HIV INTEGRASE INHIBITING EFFECT
JP2002293745A (en) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine Therapeutic agent for chronic rheumatism
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (en) 2001-07-20 2003-01-24 Lipha New quinolone acid derivatives with aldose reductase inhibiting activity, useful for prevention and treatment of diabetes-related disorders
JP4035765B2 (en) 2002-10-31 2008-01-23 横河電機株式会社 Fourier transform infrared spectrometer
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
WO1998045269A1 (en) * 1997-04-08 1998-10-15 Centre National De La Recherche Scientifique (Cnrs) Quinoline derivatives, having in particular antiviral properties, preparation and biological applications thereof
JP3567162B1 (en) 2002-11-20 2004-09-22 日本たばこ産業株式会社 4-oxoquinoline compounds and their use as HIV integrase inhibitors
EP1564210A1 (en) * 2002-11-20 2005-08-17 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063869A1 (en) * 2005-11-30 2007-06-07 Japan Tobacco Inc. Process for production of highly pure quinolone compound
JP4676536B2 (en) * 2005-12-30 2011-04-27 ギリアド サイエンシズ， インコーポレイテッド Method for improving pharmacokinetics of HIV integrase inhibitor
AU2013203476B2 (en) * 2005-12-30 2016-07-28 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007079260A1 (en) 2005-12-30 2007-07-12 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2006332664B2 (en) * 2005-12-30 2013-03-14 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of HIV integrase inhibitors
EA018544B1 (en) * 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Method for treating retroviral infection
AP2702A (en) * 2005-12-30 2013-07-23 Gilead Sciences Inc Methods for improving the pharmacokinetics of HIV integrase inhibitors
EP2308490A1 (en) 2005-12-30 2011-04-13 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP2009525265A (en) * 2005-12-30 2009-07-09 ギリアド サイエンシズ， インコーポレイテッド Method for improving pharmacokinetics of HIV integrase inhibitor
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007089030A1 (en) 2006-02-01 2007-08-09 Japan Tobacco Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
EP2452682A1 (en) 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
WO2007102512A1 (en) 2006-03-06 2007-09-13 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
US8383819B2 (en) 2006-03-06 2013-02-26 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
US8324244B2 (en) 2006-09-12 2012-12-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US8796459B2 (en) 2006-09-12 2014-08-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US7825252B2 (en) 2006-09-12 2010-11-02 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
EP2644587A2 (en) 2006-09-12 2013-10-02 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
AP2490A (en) * 2007-06-29 2012-10-04 Gilead Sciences Inc Therapeutic compositions and the use thereof
AU2008270630B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AP2965A (en) * 2007-06-29 2014-09-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
AU2008270634B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
WO2009006199A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
US8759525B2 (en) 2007-09-11 2014-06-24 Gilhead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
AP2785A (en) * 2007-09-11 2013-10-31 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
US8440831B2 (en) 2007-09-11 2013-05-14 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
EA019431B1 (en) * 2007-09-11 2014-03-31 Джилид Сайэнс, Инк. Process and intermediates for preparing integrase inhibitors
US8153801B2 (en) 2007-09-11 2012-04-10 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN101821223B (en) * 2007-09-11 2014-07-09 吉里德科学公司 Process and intermediates for preparing integrase inhibitors
KR101488550B1 (en) 2007-09-11 2015-02-02 길리애드 사이언시즈, 인코포레이티드 Process and intermediates for preparing integrase inhibitors
WO2009036161A1 (en) * 2007-09-11 2009-03-19 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2010091197A2 (en) 2009-02-06 2010-08-12 Gilead Sciences, Inc. Tablets for combination therapy
WO2010137032A3 (en) * 2009-05-14 2011-09-15 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A3 (en) * 2009-06-18 2011-04-28 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
US11548901B2 (en) 2012-12-21 2023-01-10 Gilead Sciences, Inc. Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections
US9663528B2 (en) 2012-12-21 2017-05-30 Gilead Sciences, Inc. Substituted 1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1',2'-d]pyrazines and methods for treating viral infections
US9732092B2 (en) 2012-12-21 2017-08-15 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
US10689399B2 (en) 2012-12-21 2020-06-23 Gilead Sciences, Inc. Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections
US10035809B2 (en) 2012-12-21 2018-07-31 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1′,2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections
US9421214B2 (en) 2013-07-12 2016-08-23 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US11883397B2 (en) 2013-07-12 2024-01-30 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US11213523B2 (en) 2013-07-12 2022-01-04 Gilead Sciences, Inc. Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections
US10456395B2 (en) 2013-07-12 2019-10-29 Gilead Sciences, Inc. Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections
US10668064B2 (en) 2013-07-12 2020-06-02 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9708342B2 (en) 2014-06-20 2017-07-18 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate
US10385067B2 (en) 2014-06-20 2019-08-20 Gilead Sciences, Inc. Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US10098886B2 (en) 2014-06-20 2018-10-16 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13A- octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide
US10975096B2 (en) 2014-06-20 2021-04-13 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US11202780B2 (en) 2014-06-20 2021-12-21 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US9682084B2 (en) 2014-06-20 2017-06-20 Gilead Sciences, Inc. Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US10646486B2 (en) 2014-12-23 2020-05-12 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9795602B2 (en) 2014-12-23 2017-10-24 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9522912B2 (en) 2014-12-23 2016-12-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9630978B2 (en) 2015-04-02 2017-04-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3984536A1 (en) * 2020-10-19 2022-04-20 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle
WO2022084259A1 (en) * 2020-10-19 2022-04-28 Centre National De La Recherche Scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Also Published As

Publication number Publication date
BRPI0510114B1 (en) 2020-09-15
TWI329015B (en) 2010-08-21
EP1636190A1 (en) 2006-03-22
EP4299563A3 (en) 2024-02-28
US20100204271A1 (en) 2010-08-12
ZA200610647B (en) 2008-06-25
EP3281939B1 (en) 2023-10-18
AR049280A1 (en) 2006-07-12
IL179250A0 (en) 2007-03-08
JP2006001927A (en) 2006-01-05
PT3281939T (en) 2023-11-22
CY1113010T1 (en) 2016-04-13
HUS2400006I1 (en) 2024-04-28
HUE064615T2 (en) 2024-04-28
NO20190051A1 (en) 2007-02-07
US20220235009A1 (en) 2022-07-28
CN1956961B (en) 2010-05-26
JP3754064B2 (en) 2006-03-08
SI3281939T1 (en) 2024-02-29
MY134672A (en) 2007-12-31
NO20161297A1 (en) 2007-02-07
BE2024C511I2 (en) 2024-10-08
PL3281939T3 (en) 2024-03-18
RS52375B (en) 2012-12-31
CA2566922C (en) 2011-01-11
KR20080064909A (en) 2008-07-09
US7635704B2 (en) 2009-12-22
LUC00334I2 (en) 2024-07-01
RU2330845C1 (en) 2008-08-10
NO20065790L (en) 2007-02-07
CA2566922A1 (en) 2005-12-01
AU2005245296B2 (en) 2010-08-12
US20190185433A1 (en) 2019-06-20
NO339223B1 (en) 2016-11-21
HRP20231588T3 (en) 2024-03-15
NZ551839A (en) 2009-11-27
MXPA06013405A (en) 2007-03-01
HRP20120681T1 (en) 2012-09-30
NO20220690A1 (en) 2007-02-07
FI3281939T3 (en) 2023-10-23
PE20060358A1 (en) 2006-05-12
DK3281939T3 (en) 2024-01-22
CN1956961A (en) 2007-05-02
ES2388441T3 (en) 2012-10-15
DK1636190T3 (en) 2012-09-24
ES2960824T3 (en) 2024-03-06
US8981103B2 (en) 2015-03-17
US20060030710A1 (en) 2006-02-09
PL1636190T3 (en) 2012-10-31
EP3281939A1 (en) 2018-02-14
NO20200873A1 (en) 2007-02-07
SI1636190T1 (en) 2012-09-28
BRPI0510114A (en) 2007-09-25
RS64845B1 (en) 2023-12-29
PT1636190E (en) 2012-08-20
FR23C1040I1 (en) 2023-12-29
HK1083341A1 (en) 2006-06-30
AR096100A2 (en) 2015-12-09
NO20230913A1 (en) 2007-02-07
EP2514746A1 (en) 2012-10-24
US20180029989A1 (en) 2018-02-01
NO347902B1 (en) 2024-05-06
PE20120361A1 (en) 2012-05-03
EP1636190B1 (en) 2012-06-27
US20150361044A1 (en) 2015-12-17
EP4299563A2 (en) 2024-01-03
TW200600097A (en) 2006-01-01
AU2005245296A1 (en) 2005-12-01
BRPI0510114B8 (en) 2021-05-25
FIC20240008I1 (en) 2024-03-20
LT3281939T (en) 2023-11-27

Similar Documents

Publication Publication Date Title
US20220235009A1 (en) Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US20140364389A1 (en) Combination Therapy
US7872004B2 (en) 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US7745459B2 (en) Quinolizinone compound and use thereof as HIV integrase inhibitor
KR100866296B1 (en) Stable crystal of 4-oxoquinoline compound

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2005726243

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005726243

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 179250

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2566922

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/013405

Country of ref document: MX

Ref document number: 12006502297

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 200580016142.6

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005245296

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 551839

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006/10647

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 06126877

Country of ref document: CO

Ref document number: 1020067026719

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 4680/CHENP/2006

Country of ref document: IN

Ref document number: 2006145302

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005245296

Country of ref document: AU

Date of ref document: 20050519

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005245296

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067026719

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: JP

ENP Entry into the national phase

Ref document number: PI0510114

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2012/0306

Country of ref document: RS